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General introduction 
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The prostate 
The prostate is a male gland located in the pelvis underneath the bladder, 
surrounding the urethra. It consists of fibromuscular stroma and glandular tissue, of 
which the last is responsible for prostate fluid production. This fluid is slightly acidic 
and nourishes and protects sperm. The prostate glands consist of luminal epithelial 
cells on the inside surrounded by a flat layer of basal cells on the outside. Within the 
prostate, four different zones can be defined, of which the peripheral zone, located 
on the outside, and transition zone, located in the middle, are the zones mostly 
affected by disease. 
The most commonly known affection of the prostate is benign prostate 
hyperplasia, which is an increase in the number of luminal and basal epithelial cells 
within the glands of the transition zone. As a result, the glands increase in size and 
this often leads to compression of the urethra and obstruction of the lower urinary 
tract, causing difficulties with urinating. Benign prostate hyperplasia is very common 
and occurs in most men over 75 years of age. It can be treated with medication or 
by trans-urethral resection, where small pieces of the transition zone constricting the 
urethra are surgically removed. 
In contrast to benign prostate hyperplasia, prostate cancer usually arises in 
the peripheral zone and is characterised by abnormal growth and crowding of 
malignant prostate glands. In 1853, dr. Adams was the first surgeon to describe 
prostate cancer based on histological evaluation.1 These malignant glands lack the 
basal cell layer and are lined by luminal epithelial cells only. In contrast to normal 
glands, they can invade into the surrounding fibromuscular tissue. Most prostate 
cancers are small and do not cause any symptoms, however more aggressive 
prostate cancer might cause urinary problems or blood in the urine. Most commonly, 
prostate cancers are found via a digital rectal examination or elevated serum 
prostate specific antigen (PSA). When an elevated PSA is detected in the blood, the 
urologist takes needle biopsies to establish the presence of prostate cancer. About 
10 to 12 biopsies are routinely taken and processed for pathologic review. Men with 
clinically insignificant prostate cancer are usually put on active surveillance and are 
checked by the urologist annually. 
Although most men do not have clinical significant or life-threatening 
prostate cancer, a high percentage of the patients undergoes active treatment. The 
urologist can either remove the prostate in the form of a radical prostatectomy, or 
recommend radiotherapy or hormonal therapy. All treatments are associated with 
side effects such as urinary incontinence, ejaculatory problems and erectile 
dysfunction. Radiotherapy is also applied in case the tumour recurs after surgery. 
Even though it is the most diagnosed form of cancer in Western men and 
approximately one out of six men above the age of 60 will develop prostate cancer, 
only one in 33 men will die of the disease.2  
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Prostate cancer pathology 
Developments in the field of pathology in terms of tissue slicing and staining started 
in the 19th century with the introduction of the microscope, tissue fixation and 
embedding, and subsequent thin slicing.3 Nowadays, tissue is collected after biopsy 
or operation, then thoroughly fixated with formalin and finally embedded in paraffin. 
Within the Erasmus MC, every prostate biopsy core is collected, fixated and 
embedded separately, ensuring adequate recording of the biopsy site. The 
embedded biopsies are then sectioned and stained at three levels to ensure 
adequate visualisation of the total biopsy core, as fewer levels may miss foci of 
cancer. To visualise different structures and cellular properties of the tissue, contrast 
is applied by means of the hematoxylin and eosin (HE) stain, which counts as the 
cornerstone of pathology.4 The HE stain colours the nuclei of the cells violet and the 
cytoplasm of the cells pink. In addition, a broad range of specific protein-targeting 
antibodies is available to distinguish specific cells or cell types, visualised by 
immunohistochemistry.5  
After staining, the tissue is examined by the pathologist. In case of prostate 
cancer, the tumour is graded microscopically using the Gleason scoring system, 
developed by Donald Gleason in the 1960s and used worldwide. This grading 
system is based on the great variability of growth patterns of the cancerous glands 
on histological slides and their varying prognosis.6 Five different prostate cancer 
grades are recognised and a higher grade is associated with a more aggressive 
cancer. Since most patients show presence of multiple growth patterns, the sum of 
the two most predominant grades determines the final Gleason score. Gleason 
grade 1 consists of small well-delineated glands which are surrounded by a nodular 
stroma capsule, not invading the stroma of benign prostate glands. Grade 2 shows 
the same morphology as grade 1 but the glands have a more variable diameter. In 
grade 3 the glands infiltrate the surrounding stroma but still retain a similar 
morphology. Grade 4 consists of less differentiated glands with a wide morphologic 
variability, such as poorly-formed glands with irregular lumens and shapes, 
glomeruloid glands, fused glands and cribriform glands. Grade 5 consists of 
undifferentiated cells which lack obvious glandular formation and is subdivided in the 
patterns single cells, cords and solid fields (Fig. 1).5, 7  
Histopathological characterisation of prostate cancer at diagnostic biopsies 
is important for the choice of therapy for the patient. Therefore it is important to 
realise that there is a high rate of undersampling when taking prostate biopsies. In 
up to 40% of the cases, the Gleason score is upgraded on subsequent radical 
prostatectomy specimens, which can have major impact on patient outcome and 
management.8 A biopsy Gleason score of ≤3+3=6 is considered clinically 
insignificant and active treatment is often not necessary. On the other hand, patients 
with Gleason score ≥3+4=7 usually receive active treatment for their disease. Recent 
studies have shown that the individual growth patterns in Gleason score ≥3+4=7 
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have prognostic value as well. Currently, many pathologists do not mention these 
patterns separately in their reports. Especially for the cribriform growth pattern, it is 
of importance to investigate the rate of undersampling, for patients with presence of 
cribriform growth have adverse outcome.9 
 
 
 
Prostate biopsy processing and grading 
Pathology reports of prostate biopsies 
contain detailed histopathological 
characterisation of the tumour. For each 
prostate cancer positive biopsy for 
instance the Gleason score and extent of 
cancer are mentioned. In addition, high-
grade prostate epithelial neoplasia and 
intraductal carcinoma are reported 
separately.10 However, these aberrant 
glands do not influence the cancer 
grade. Presence of perineural invasion is 
usually also reported.11  
 
 
 
 
 
 
Figure 1. Gleason grading according to the 
International Society of Urological Pathology 2014 
consensus meeting.6 
 
 
In case the distinction between prostate cancer and benign lesions is not evident, 
immunohistochemical stainings can be done. To discern cancer from benign 
mimickers, a basal cell staining such as Keratin 5 or p63 may be done to visualise 
the presence or absence of basal cells. However, the basal layer is not always 
evident in benign lesions mimicking prostate cancer, and therefore additional 
stainings may be performed. For instance, in the majority of cases prostate cancer 
strongly expresses the alpha-methylacyl-CoA-racemace (AMACR) protein, which is 
a clear marker to confirm the definitive diagnosis.12 More recently available 
immunostaining for the ETS-related gene (ERG) can also be used, for it is a very 
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specific prostate cancer marker, however this protein is only present in 50% of the 
prostate cancer patients.13  
When prostate cancer is diagnosed, a Gleason score is assigned to each 
individual biopsy core. However, due to tumour heterogeneity individual cores might 
have a different Gleason score. In this case, an overall Gleason might be given for 
the entire case. At this moment it is not clear yet whether the individual Gleason 
score or the overall Gleason score for the entire case should be used for clinical 
decision making. 
 The pathology report also states the tumour extent of the biopsies containing 
prostate cancer. However, the parameter for reporting tumour extent on prostate 
biopsies has not yet been standardised. Several parameters have been proposed 
as measure of tumour extent, for example absolute tumour length, tumour 
percentage of only prostate cancer positive cores and tumour percentage of all 
biopsies including the negative cores.14 Both absolute tumour length and tumour 
percentage have been associated with pathological staging and outcome after 
radical prostatectomy.15-18 Tumour length is usually measured using a ruler, whereas 
tumour percentages are often estimated by eye-balling. It is not yet clear whether all 
different tumour volume parameters have a similar prognostic value and this should 
be studied further. 
 
Three-dimensional imaging  
Recently, it has been shown that individual Gleason growth patterns have distinct 
prognostic impart. Pathologic reporting and biological investigation of individual 
growth patterns will give better clinical and mechanistic insight in prostate cancer, 
and therefore it is important to define these growth patterns. However, routine 
pathological grading is done on thin sectioned tissue slices of approximately 5 µm 
whilst prostate cancer grows three-dimensionally. Since tissue scatters light, it is not 
feasible to use sections much thicker than 5 µm, limiting the understanding of actual 
growth of the prostate cancer patterns. As the 3D morphology might elucidate mutual 
relations between growth patterns and explain the inter-observer variability between 
some growth patterns, there is need for development of a robust protocol to visualise 
tissue structures in their native 3D environment. The most commonly used method 
for 3D reconstruction is serial slicing and stacking of thin slices, which enables 
imaging of large areas of interest. The advantage of this technique is the 
preservation of pathologic features to which pathologists are accustomed. However, 
this method is very labour- and time intensive, and highly sensitive to cutting 
artefacts. Also, registration and alignment of these tissue slices can be 
problematic.19, 20 Algorithms for proper alignment are under construction to develop 
fully automated methods to reassemble continuous volumes, whilst minimizing 
deformations due to bad registration.21-25 Another disadvantage of serial slicing and 
stacking is that the method is tissue destructive and does not allow further analysis 
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or staining of used slices. In the past, several studies have shown the feasibility of 
serial slicing in the reconstruction of prostate tissue.26-31 
A different method to visualise 3D structures is the use of whole tissue 
processing and imaging, allowing full view of the structures without the need of 
sectioning. However, structures within the tissue are obscured by intrinsically 
scattered light hindering visualisation of structures at lower levels. Due to this, 
evaluation of thick tissue sections by light or fluorescent microscopy is limited to 
depths of up to 10-20 micrometre. Beyond this depth over-projection of tissue 
structures severely inhibits visualisation. Use of confocal laser scanning microscopy 
(CLSM) has enabled visualisation of structures lying deeper within the tissues, up to 
a depth of 70 micrometres. However, beyond this depth emitted fluorescent light is 
scattered by the molecular structures in the intervening tissue between the 
fluorescent source and the camera. Therefore imaging at deeper levels can only be 
performed when light scattering is eliminated through for instance clearing of the 
tissue by matching the refractive indexes of both tissue and surrounding medium.  
A century ago Spalteholtz was the first to describe such method with a 
laborious clearing technique for large tissues using organic solving agents. 
Unfortunately this technique damaged the upper layer of the tissues and was only 
useful for clearing of large samples.32, 33 Another method is the removal of fatty acids 
in the tissue by electrophoresis and subsequent submerging of the tissue in a 
clearing agent which removes scattering and allows for imaging of fluorescent 
proteins deep within the tissue.34 Recently, new advances have been made in the 
field of solvent-based tissue clearing, which can be applied to archival fixated and 
embedded tissue. The clearing capacity of these new solvents is based on the 
dehydration of the tissue and subsequent matching of the refractive index of the 
tissue with that of the organic solvent, resulting in optical clearing.35 In combination 
with confocal laser scanning microscopy and fluorescent immunostaining this allows 
visualisation of formalin-fixed, paraffin embedded tissues up to a depth of 1 mm. The 
recent advances create opportunities for 3D visualisation of prostate cancer tissues, 
enabling imaging of structures deep within the tissue.  
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The scope of this thesis is to reveal the three-dimensional morphology of prostate 
cancer and its benign mimickers and to investigate parameters predictive for patient 
outcome on prostate cancer biopsies. In more detail, in this thesis: 
 
 A tissue clearing method was optimised for use with archival formalin-fixed 
paraffin-embedded prostate tissues (Chapter II). This opened the 
opportunity to study specific structures within their three-dimensional 
context, while tissue remained suitable for subsequent two-dimensional 
analysis. 
 
 The three-dimensional structures of prostate epithelial structures were 
extensively visualised. We investigated the actual growth of common benign 
lesions (Chapter III) as well as the morphology of individual prostate cancer 
growth patterns (Chapter IV) in intact tissue samples. 
 
 Presence of cribriform growth at biopsy and subsequent radical 
prostatectomy was investigated, as well as parameters predictive for 
outcome of patients with false-negative biopsies (Chapter V). 
 
 The characteristics and outcome of prostate cancer patients with overall 
Gleason score 3+4=7 and highest individual Gleason score > 3+4=7 on 
biopsy were determined (Chapter VI). 
 
 Five tumour volume parameters were compared in relation to outcome after 
radical prostatectomy or radiotherapy (Chapter VII). 
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CHAPTER II 
 
Three-dimensional microscopic analysis  
of clinical prostate specimens 
 
van Royen*, Verhoef EI*, Kweldam CF, van Cappellen WA, Kremers GJ, 
Houtsmuller AB, van Leenders GJ 
Histopathology 2016 Dec;69(6):985-992 
* These authors contributed equally to this paper 
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ABSTRACT 
Aims: Microscopic evaluation of prostate specimens for both clinical and research 
purposes is generally performed on 5 µm thick tissue sections. Because cross-
sections give a two-dimensional (2D) representation, little is known about the actual 
underlying three-dimensional (3D) architectural features of benign prostate tissue 
and prostate cancer. The aim of this study was to show that a combination of tissue-
clearing protocols and confocal microscopy can successfully be applied to 
investigate the 3D architecture of human prostate tissue. 
 
Methods and results: Optical clearing of intact fresh and formalin-fixed paraffin-
embedded (FFPE) clinical prostate specimens allowed us to visualise tissue 
structures up to a depth of 800 µm, whereas, in un-cleared tissue, detection of 
fluorescence was only possible up to 70 µm. Fluorescent labelling with a general 
nuclear dye and antibodies against cytokeratin (CK) 5 and CK 8-18 resulted in 
comprehensive 3D imaging of benign peripheral and transition prostate zones, as 
well as individual prostate cancer growth patterns. After staining, clearing and 
imaging, samples could still be processed for 2D (immuno)histochemical staining 
and DNA analysis, enabling additional molecular and diagnostic characterisation of 
small tissue specimens.  
 
Conclusions: In conclusion, the applicability of 3D imaging to archival FFPE and 
fresh clinical specimens offers unlimited opportunities to study clinical and biological 
topics of interest in their actual 3D context. 
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INTRODUCTION 
The Gleason grade is an important parameter for therapeutic decision-making and 
predicting outcome of patients with clinical prostate cancer, and is entirely based on 
architectural tumour growth patterns.36 Pathological investigation for both diagnostic 
and research purposes is routinely carried out by microscopic evaluation of 4 to 5 
μm thick tissue slides, resulting in a two-dimensional (2D) tissue cross-section. In 
fact, little is known about the actual three-dimensional (3D) architecture of diseases 
such as prostate cancer.  
Three-dimensional microscopic tissue reconstruction has mostly been 
carried out by serial sectioning, staining and imaging of up to hundreds of 2D 
sections.37-39 Although developments in image stacking have improved 3D 
reconstruction, serial slicing is laborious and sensitive to tissue deformations.40-43 
Confocal laser scanning microscopy (CLSM) allows fluorescent 3D imaging without 
the need of sectioning, but is limited to depths of tens of micrometres owing to 
scattering and absorption of emitted fluorescent light. Several protocols have 
recently been developed to optically clear tissue and thereby enhance the detection 
of emitted fluorescent light at increased tissue depths.35, 44-48 Three-dimensional 
imaging by combination of tissue clearance and CLSM has predominantly been used 
for investigation of mouse models, sometimes primarily labelled with green 
fluorescent protein.34, 46, 49 The aim of the current study was to investigate the 
feasibility of using tissue clearing protocols and imaging techniques on fresh and 
formalin-fixed paraffin-embedded (FFPE) prostate specimens, in order to analyse 
both clinical and biological prostate cancer features in their actual 3D context. 
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MATERIALS AND METHODS 
Clinical specimens 
Prostate samples were derived from radical prostatectomies, performed at Erasmus 
Medical Centre, Rotterdam, The Netherlands between September 2014 and March 
2016. Use of fresh and archival tissue samples for research purposes was approved 
by the local Medical Ethical Committee (MEC 2011-295 and 2011-296). After arrival 
at the pathology department, fresh samples of 5 x 5 mm from both normal and 
tumour tissue were collected for 3D imaging (N=13). From each sample a 1 mm slice 
was cut and processed for reference 5 µm slice hematoxylin & eosin (HE) staining. 
Tissue samples for 3D imaging were sliced within 24 hours in ice-cold Phosphate 
Buffered Saline (PBS) using a vibrating blade microtome Leica VT 1200 S (Leica, 
Rijswijk, The Netherlands). Slices of 500 to 1000 µm thickness were fixed overnight 
in 1% formaldehyde in PBS at 4°C. After fixation tissue slices were washed in PBS, 
gradually incubated in methanol/PBS up to 100% methanol, and stored at -20°C until 
further processing. 
 
Staining of formalin-fixed non-embedded tissue 
Fixation, staining and clearing of fresh, non-embedded tissue was performed as 
described previously.50 Briefly, fixed tissue was rehydrated in methanol/PBS 
gradients up to 100% PBS, and blocked in PBS-1% non-fat dry milk- 0.4% Triton 
X100. This was followed by incubation with RedDot2 (1:400; Biotium, Hayward, 
USA) fluorescent nuclear dye, or primary antibodies targeting cytokeratin (CK) 5 
(1:100, ab52635; AbCam, Cambridge, UK) and CK8-18 (1:100; MS-743S, 
Immunologic, Duiven, The Netherlands) in PBS-1% non-fat dry milk- 0.4% Triton 
X100 for a minimum of 7 days. After washing in PBS/0.4% Triton X100, specimens 
were incubated with secondary Alexa 514- or Alexa 647-conjugated antibodies 
(1:200; Life Technologies, Bleiswijk, The Netherlands) in PBS-1% non-fat dry milk- 
0.4% Triton X100 for 7 days. Subsequent washing steps in PBS/0.4% Triton X100 
were followed by gradient tissue dehydration in methanol. Prior to clearing, tissues 
were incubated with a mixture of 50% methanol and 50% 1:2 benzyl alcohol:benzyl 
benzoate (BABB) solution (Sigma, Zwijndrecht, The Netherlands) for 10 minutes. 
Optical transparency was achieved after incubation with 100% BABB solution for 10 
minutes. Tissue was stored in BABB at 4°C until imaging for a maximum of four 
weeks. 
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Staining of FFPE tissue 
For 3D imaging of archival FFPE prostate samples (N=38), areas of interest were 
indicated on coverslips of HE stained slides derived from diagnostic biopsies and 
radical prostatectomy specimens. Punches of 500 µm thickness were collected from 
the corresponding FFPE block using tissue micro-array punching needles (Estigen 
Tissue Science, Tartu, Estonia). 3D immunofluorescent tissue staining was 
performed according to the iDISCO protocol.49 Briefly, tissues were de-waxed 
overnight and subsequently incubated in methanol for 60 minutes, incubated in 20% 
dimethylsulfoxide (DMSO), 20% H2O2 in methanol at 4°C, followed by overnight 
incubation in 20% DMSO in methanol. Tissue was rehydrated gradually in 
methanol:PBS, followed by a blocking step with 0.2%TritonX100/10%DMSO/0.3M 
Glycine/PBS. Primary antibodies targeting CK5 (1:100) and CK8-18 (1:100) were 
incubated for 7 days in 0.2%/Tween/20-10ug/ml Heparin/5%DMSO/1%Milk/PBS at 
37°C, followed by washing in 0.2% Tween20/20-10ug/ml Heparin/PBS and 
incubation with secondary fluorescent Alexa 514- or Alexa 647-labelled antibodies 
(1:200, Life Technologies, Bleiswijk, The Netherlands) in 0.2%Tween20/10ug/ml 
Heparin/5%DMSO/1%Milk/PBS for 7 days at 37°C. Prior to clearing, tissue was 
washed in 0.2%Tween20/10ug/ml Heparin/PBS overnight at 37°C, dehydrated in 
methanol gradients at room temperature and subsequently incubated in a mixture of 
50% methanol and 50% BABB. Optical transparency was achieved in 100% BABB 
solution after 10 minutes incubation. After clearing, tissue was stored for a maximum 
of four weeks in BABB at 4°C until imaging. 
 
Confocal microscopy 
For imaging the samples were mounted in 100% BABB in glass bottom microwell 
dishes (MatTek corp, Ashland (MA), USA) and covered with #1 coverglasses 
(Menzel-Gläser, Braunschweig, Germany) to avoid direct contact of the microscope 
objective with the BABB. Imaging was done using an upright Leica SP5 confocal 
microscope (Leica Microsystems, Eindhoven, The Netherlands) equipped with a 20x 
NA1.0 APO water dipping objective with a 1.95 mm working distance through a 170 
µm thick coverslip. Z-stacks were recorded with a 0.72 µm pixel size and a 1 to 3 µm 
step-size in Z, using a 488 Argon and a 633 HeNe laser. Emission was detected in 
the 525-600 nm and 643-700 nm emission ranges, respectively. To compensate loss 
of signal and optimise the collection of structural information, laser intensity and 
detector sensitivity were (semi-)automatically adjusted within a pre-set range. The 
settings were identical within each experiment. Images were de-convoluted using 
the Huygens Professional software (SVI, Hilversum, The Netherlands). 3D rendering 
and image editing was performed with Fiji (ImageJ 1.49s) and Amira (version 5.5.0, 
FEI, Hillsboro, Oregon, USA) software.51 
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Immunohistochemistry 
For subsequent 2D immunohistochemistry, cleared and 3D imaged tissues were 
returned to 100% methanol. Methanol was replaced by ethanol, and tissue was 
gradually rehydrated in PBS for re-embedding in paraffin. Five micron FFPE sections 
of post-cleared tissues were deparaffinised and rehydrated using xylene and 
ethanol. Endogenous peroxidase was blocked in 0.3% H2O2 in PBS and heat-
induced antigen retrieval was performed for 15 minutes in TRIS-EDTA buffer (pH=9; 
Klinipath, Duiven, The Netherlands). Primary antibodies targeting CK8-18 (1:500), 
CD31 (1:500; AbCam, Cambridge, USA), KI67 (1:200; DAKO, Heverlee, Belgium) 
and Vimentin (1:500; DAKO) diluted in normal antibody diluent (APG-500, Scytek, 
Utah, USA) were incubated overnight at 4°C and visualised using the Envision kit 
(DAKO). Slides were counterstained with hematoxylin and visualised on an Olympus 
BX41 light microscope (Olympus, Zoeterwoude, The Netherlands).  
 
Molecular analysis 
BABB cleared tissues were placed in methanol and rehydrated in methanol:PBS 
gradients. DNA from tissue punches was isolated in lysis buffer (Promega, Leiden, 
The Netherlands) containing 5% chelex (Bio-Rad, Veenendaal, The Netherlands) 
with protease K (Promega) overnight at 56°C. Protease deactivation was achieved 
by heating to 95°C for 10 minutes. PCR was performed with primers for 
housekeeping genes TBXAS1, RAG1, PLZF and AF4 for 35 cycli at 60°C. DNA from 
non-cleared FFPE prostate samples served as control. DNA concentration and purity 
were measured of 6 fresh cleared and 6 FFPE cleared tissues using the Nanodrop 
system (Thermo Scientific, Wilmington, USA). As a control, 0.5 mm punches of 2 
non-cleared samples derived from the same patients were included. 
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RESULTS 
Three-dimensional imaging of fresh prostate tissue 
To evaluate the efficacy of tissue clearing, we first compared fluorescent staining in 
cleared versus non-cleared prostate tissue samples (n=4). Thick tissue slices were 
stained with RedDot2 and imaged using CLSM. Nuclear RedDot2 signals could be 
detected throughout the whole BABB cleared tissue slice of 800 μm. Without tissue 
clearing, the Reddot2 signal was lost at 70 µm within the tissue, and was only visible 
at the edges of the tissue up to a depth of 200 μm in the image stack (Fig. 1; Suppl. 
Fig. 1).  
 
 
Figure 1. Tissue clearing of fresh clinical prostate cancer tissue. A three-dimensional projection of 
fluorescent images of A) nuclear Reddot2 in non-cleared and B) benzyl alcohol/benzyl benzoate-cleared 
clinical prostate tissue showed that tissue clearing enhanced the depth of imaging up to 0.8 mm. Scale 
bars: 100 µm. 
 
To gain insights into 3D normal and malignant prostate glandular architecture, we 
performed IF double-staining for CK5 and CK8-18.52, 53 In general, CK5 labels pre-
existent basal cells surrounding CK8-18-positive luminal epithelial cells in benign 
prostate glands. Prostate cancer almost exclusively exists of CK8-18-positive 
luminal cells and lacks a CK5-positive basal cell layer.54, 55 By using IF double-
labelling, we were able to routinely image approximately 500 µm thick tissues with 
sufficient signal throughout the stack. In the transition zone, 2D well-delineated 
round glandular structures were represented in three dimensions by organised acini 
(Fig. 2A-D, Suppl. Video 1). In the peripheral zone, 2D longitudinal tubule sections 
corresponded to 3D slit-like angulated tubular spaces (Fig. 2E-H, Suppl. Video 2). 
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Figure 2. Three-dimensional imaging of antibody-stained fresh samples of benign prostate transition zone 
(A–D) and peripheral zone (E–H). A,E) Reference hematoxylin and eosin slide. B,F) Single two-
dimensional optical plane of immunofluorescent cytokeratin (CK) 8-18 labelled (green) and CK5-labelled 
(red), benzyl alcohol/benzyl benzoate-cleared tissue. C,G,D,H) Three-dimensional projection (C,G) and 
3D binary projection (D,H) of approximately 500-lm-thick tissue samples. Scale bars: 100 µm. 
 
3D imaging of FFPE prostate tissue  
The feasibility of clearing and 3D imaging on archival FFPE tissue samples was 
investigated at selected prostate cancer growth patterns on HE stained slides. Fig. 
3A-D demonstrates closely packed well-delineated glands corresponding to Gleason 
score 3+3=6 prostate cancer; on HE branching and anastomosing of glands was not 
observed. Remarkably, 3D immunofluorescent imaging illustrated that respective 
prostate cancer glands actually represented an interconnecting glandular network 
(Suppl. Video 3). A Gleason score 7 prostate cancer consisting of well-delineated 
Gleason pattern 3 glands and Gleason pattern 4 with intra-luminal glomeruloid 
epithelial proliferations is depicted in Fig. 3E-H (Suppl. Video 4). 3D reconstruction 
revealed spatial transition of well-delineated Gleason pattern 3 glands and 
glomeruloid Gleason grade 4 patterns. The glandular structures with intra-luminal 
glomeruloid proliferations were continuous with well-delineated Gleason grade 3 
glands, which was not appreciated in the corresponding HE slide. Fig. 3J-L depicts 
an area of ill-defined Gleason pattern 4 prostate cancer glands. 3D analysis revealed 
that these structures represented a highly anastomosing meshwork of small-sized 
tubules and cords of malignant cells (Suppl. Video 5). The inter observer variability 
of ill-defined tumour glands is relatively poor, as discriminating them from 
tangentially sectioned Gleason grade 3 or Gleason grade 5 is often difficult.43 While 
the pattern is different from classical Gleason grade 3 (Fig. 3A-D), the 3D 
architectural differences between ill-defined Gleason grade 4 and Gleason grade 5 
cords is not clear yet. 
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Figure 3. Three-dimensional (3D) pathology of prostate cancer growth patterns. A–D) Well-delineated 
Gleason grade 3 prostate cancer with regular 3D glandular interconnections. E–H) Well-delineated 
Gleason grade 3 and glomeruloid Gleason grade 4 glands. Three-dimensional spatial transitions between 
both structures exist. I–L) Three-dimensional projection of an ill-defined Gleason grade 4 gland 
demonstrates a highly interconnecting meshwork of small-sized tubules and cords. Vertical panels from 
left to right represent a reference hematoxylin and eosin slide, a single 2D optical plane of 
immunofluorescent cytokeratin (CK) 8-18-labelled (green) and CK5-labelled (red) benzyl alcohol/benzyl 
benzoate-cleared tissue, and original 3D and 3D binary projections. Scale bars: 100 µm. 
 
Tissue processing after 3D imaging  
To determine whether subsequent 2D immunohistochemistry and molecular analysis 
were compatible with 3D immunofluorescence and BABB clearing, we rehydrated 
and paraffin-embedded tissue samples after clearing and imaging. Tissue 
morphology on HE staining before and after 3D processing was comparable. 
Conventional immunohistochemical staining for CK8-18, CD31, Ki67 and Vimentin 
(Fig. 4A) demonstrated that specific protein labelling after 3D imaging is still feasible. 
In the CD31, KI67 and Vimentin staining in fresh tissue, basal epithelial cell staining 
was observed, due to presence of CK5 antibody with a high antigen affinity, added 
for 3D fluorescent imaging, and shared primary antibody hosts (Suppl. Fig. 1C).  
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Figure 4. Processing of cleared formalin-fixed paraffin-embedded archival prostate cancer tissue. A) 
Immunohistochemical cytokeratin (CK) 8-18, CD31, Ki67 and Vimentin staining of cleared, re-embedded 
tissue sections demonstrates labelling of luminal epithelium, endothelium, proliferating cells, and stromal 
cells (arrowheads). B) Routine quality polymerase chain reaction on DNA isolated from cleared tissue 
samples shows the applicability of molecular analysis after 3D imaging, despite some degradation as 
compared with control non-cleared tissue. 
 
After BABB clearing and 3D imaging, DNA could be isolated, amplified using 
PCR and analysed, however some degradation was observed (Fig. 4B and Suppl. 
Fig. 1D). DNA yield was sufficient for multiple DNA analysis (range 68.4 – 202.7 
ng/µl) with minor loss of purity (range 0.7-1.1, Table 1). RNA isolation resulted overall 
in small amounts of degraded RNA (range 2.3 – 4.9 ng/l, purity range 1.3 – 6.8), 
which was non-sufficient for RNA analysis. 
Table 1. DNA yield and purity of cleared and uncleared tissues. 
  Yield in ng/µl (SD) Purity (SD) 
FFPE cleared (n=6) 68.4 (13.9) 0.7 (0.0) 
FFPE uncleared (n=2) 145.8 (41.2) 1.0 (0.1) 
Fresh cleared (n=6) 202.7 (96.2) 1.1 (0.2) 
Fresh uncleared (n=2) 163.7 (2.9) 1.1 (0.0) 
FFPE, formalin-fixed paraffin-embedded; SD, standard deviation  
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DISCUSSION 
In this study, we have demonstrated that BABB mediated tissue clearing can 
successfully be applied for 3D imaging of fresh and FFPE clinical prostate specimens 
up to a depth of approximately 1000 µm. The feasibility of this methodology on FFPE 
tissues, particularly, offers the opportunity to study specific histopathologic areas of 
interest in their 3D context. We have also shown that, after 3D imaging, tissue 
samples are still suitable for routine 2D processing including immunohistochemistry 
and molecular analysis. The latter feature is of importance since 3D imaging has 
been raised as a novel diagnostic tissue processing methodology in the future.56 
In this study, we were able to image small nuclear dyes and antibodies up 
to a depth of approximately 1000 µm, visualizing the 3D microscopic structure of 
both benign and malignant human prostate samples. We set out to develop 3D 
imaging in clinical prostate tissues to get more profound insight in prostate cancer 
growth patterns underlying the current Gleason grading system. A significant 
limitation of Gleason grading is its substantial inter-observer variability.37-39, 43 This 
particularly accounts for distinguishing well-delineated Gleason grade 3 glands from 
ill-defined and fused Gleason grade 4 prostate cancer structures. Whereas Gleason 
score 6 prostate cancer patients are often eligible for active surveillance, patients 
with Gleason score 7 generally undergo active treatment, e.g. radical prostatectomy 
or radiotherapy.57 This implies that inter-observer variability in distinguishing 
Gleason grade 3 and 4 patterns is of clinical relevance for individual patients. In 
active surveillance cohorts, for instance, 10% of patients would have had received 
different treatment recommendations based on pathologic re-evaluation of their 
biopsy samples.39 Inter-observer agreement could be optimised by large-scale 
training sets or more detailed definition of distinguishing features. We hypothesise 
that providing comprehensive insight in 3D prostate growth pattern architectures will 
facilitate the interpretation of routine 2D diagnostic slides. While detailed 
characterisation of various growth patterns was not within the scope of this study, 
we were able to preliminarily interpret a subset of growth patterns i.e. we have shown 
that 1) Gleason grade 3 glands are branching and connecting, and 2) ill-defined 
Gleason grade 4 glands represent small tubules with more frequent 
interconnections. Instead of separate Gleason grades, both patterns seem to 
represent a continuum of tubular glands, showing differences in circumference and 
lumen volume. This could explain their considerable inter-observer variability. More 
extensive analysis of various growth patterns may further elucidate their 3D 
characteristics. 
While 3D imaging is currently only used for research purposes, clearing 
techniques might offer an opportunity for diagnostic pathology in the future. Torres 
et al. demonstrated comparable morphology between BABB cleared of up to 1000 
µm thick samples imaged by multi-photon microscopy with pseudo-colouring and 
reference HE 2D slides.56 Advantages of such an approach would be that tissue 
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samples remain intact and no material is lost due to tissue sectioning. We have 
showed that 2D immunohistochemistry and molecular analysis can still be performed 
on optically cleared tissue used for 3D imaging. With the current technological 
advancements in view, including light sheet microscopy, deep tissue scanning and 
optimisation of staining protocols, imaging of intact tissue samples might become an 
alternative to traditional 2D HE stained tissue slides in the future.  
Current 3D imaging has few limitations. Passive antibody diffusion results in 
penetration for only up to 500 µm in one week, which hampers the depth of tissue 
imaging. Whereas diffusion of small fluorescent molecules is significantly faster, 
modifications in antibody staining methodology such as incubation under pressure 
might accelerate staining procedures. Secondly, interpretation of 3D, as well as 
routine 2D growth patterns is subjective and requires the development of algorithms 
to more objectively describe and separate tissue structures. 
In conclusion, we have described a methodology for clearing and 3D 
imaging of fresh and FFPE prostate specimens up to a depth 1000 µm. This 
methodology allows 3D analysis of an unlimited range of normal and pathologic 
structures in clinical tissue specimens. The procedure is compatible with subsequent 
tissue sectioning, 2D (immuno)histochemistry and molecular analysis, which are 
prerequisite adjuncts in current diagnostic practice. 
 
Supplementary Figures and Videos may be found in the online version of this 
article. 
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ABSTRACT 
 
Aims: Many glandular lesions can mimic prostate cancer microscopically including 
atrophic glands, adenosis and prostate intraepithelial neoplasia. While the 
characteristic histopathological and immunohistochemical features of these lesions 
have been well established, little is known about their three-dimensional architecture. 
Our objective was to evaluate the three-dimensional organisation of common 
prostate epithelial lesions.  
 
Methods and results: Five hundred micron thick punches (n=42) were taken from 
radical prostatectomy specimens, and stained with antibodies targeting Keratin 8-18 
and Keratin 5 for identification of luminal and basal cells respectively. Tissue 
samples were optically cleared in benzyl alcohol: benzyl benzoate and imaged using 
a confocal laser scanning microscope. The three-dimensional architecture of 
peripheral and transition zone glands was acinar, composed of interconnecting and 
blind-ending saccular tubules. In simple atrophy, partial atrophy and post-atrophic 
hyperplasia, the acinar structure was attenuated with branching blind-ending tubules 
from parental tubular structures. Three-dimensional imaging revealed a novel variant 
of prostate atrophy characterised by large Golgi-like atrophic spaces parallel to the 
prostate surface, which were represented by thin, elongated tubular structures on 
HE slides. Adenosis on the other hand lacked acinar organisation, so that it closely 
mimicked low-grade prostate cancer. High-grade prostate intraepithelial neoplasia 
displayed prominent papillary intra-luminal protrusions but retained an acinar 
organisation, whereas intraductal carcinoma predominantly consisted of cribriform 
proliferations with either spheroid, ellipsoid or complex interconnecting lumens. 
 
Conclusions: While various prostate epithelial lesions might mimic malignancy on 
HE slides, their three-dimensional architecture is acinar and clearly different from the 
tubular structure of prostate cancer, with adenosis as exception. 
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INTRODUCTION 
 
The vast majority of prostate cancers are diagnosed on histopathological slides of 
transrectal or transperineal biopsies prompted by an elevated Prostate Specific 
Antigen (PSA) serum level or lower urinary tract symptoms. Prostate cancer 
diagnosis is usually straightforward and does not require supportive 
immunohistochemical staining in most cases. However, immunohistochemistry with 
Keratin 5, p63, alpha-methylacyl-CoA racemase (AMACR) and ETS-related gene 
(ERG) antibodies can be used for accurate diagnosis of small tumour foci and for 
distinction from benign glandular mimickers.58-62 
Many glandular lesions can resemble prostate cancer.63, 64 Glandular 
atrophy most frequently enters the differential diagnosis with conventional prostate 
cancer.65 Atypical adenomatous hyperplasia, or adenosis, and high-grade prostate 
intraepithelial neoplasia are other common lesions with resemblance prostate 
cancer. While immunohistochemical stains can aid decision-making, the 
classification of a small number of lesions remains uncertain and these have been 
referred to as atypical small acinar proliferations.66  
Histopathological evaluation is generally performed by microscopic analysis 
of 4-5 µm hematoxylin & eosin (HE) stained tissue slides. Our knowledge of 
histopathology and conventional diagnostic criteria is therefore entirely based on 
two-dimensional features. Little is known about the three-dimensional (3D) 
architecture of normal prostate glands, benign epithelial lesions and prostate cancer. 
Recent developments in the field of optical tissue clearing allow for sensitive deep 
fluorescent imaging of tissue specimens. While these techniques have mostly been 
used for studying in vitro and animal models, we have recently adapted the 
methodology for use on formalin-fixed, paraffin-embedded prostate tissues. This 
allows 3D imaging of specific regions of interest.67 In this study we aimed to clarify 
the 3D architecture of the most common benign and pre-cancerous prostate 
glandular lesions.  
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MATERIALS AND METHODS 
 
Case selection 
A selection of archival formalin-fixed, paraffin-embedded radical prostatectomy 
specimens from patients who had undergone radical prostatectomy at the Erasmus 
Medical Centre in Rotterdam between 2012 and 2017 was made. These tissue 
specimens were fixed in neutral-buffered formalin and routinely processed for 
histopathologic evaluation. A urogenital pathologist (GvL) indicated regions of 
interest on 5 µm thick HE stained tissue slides. In total, 42 areas from 32 patients 
were used. These areas included glands from the normal peripheral (n=3) and 
transition zone (n=7), simple atrophy (n=6), cystic atrophy (n=5), post-atrophic 
hyperplasia (n=1), partial atrophy (n=2), adenosis (n=4), high-grade prostate 
intraepithelial neoplasia (n=9) and intraductal carcinoma (n=5), as well as one 
prostate cancer case for reference purposes. The use of tissue samples for scientific 
purposes was approved by the institutional Medical Research Ethics Committee 
(MEC-2011-295, MEC-2011-296). Samples were used in accordance with the “Code 
for Proper Secondary Use of Human Tissue in The Netherlands” as developed by 
the Dutch Federation of Medical Scientific Societies (FMWV, version 2002, update 
2011). 
 
Immunofluorescent staining and optical clearing 
The total workflow is depicted in Fig. 1. Tissue punches from the regions of interest 
were taken from the corresponding paraffin blocks using a 500 µm diameter needle 
(Estigen, Tartu, Estonia) ) resulting in 3-4 mm long cylindrical tissue cores with a 
diameter of 500 µm. Immunofluorescent staining was performed according to an 
adapted iDISCO protocol as described previously.49, 67 In short, punches were 
dewaxed and this was followed by an auto-fluorescence blocking step. Thereafter 
the tissue punches were gradually rehydrated and incubated with Keratin 5 and 
Keratin 8/18 targeting antibodies (1:150; EP1601Y; Abcam, Cambridge, UK and 
1:75; MS-743; Immunologic, Duiven, The Netherlands). These were visualised with 
secondary fluorescent Alexa 514- and Alexa 647-labelled antibodies (1:200; Life 
Technologies, Bleiswijk, The Netherlands). After dehydration in methanol, an optical 
clearing step was performed by immersing the tissue in benzyl-alcohol: benzyl 
benzoate until optical transparency was achieved. Samples were stored at 4°C in 
the dark until imaging.  
 
Sample imaging 
Confocal fluorescent imaging was done with an upright Leica SP5 confocal 
microscope fitted with a 1.95 mm working distance 20x NA1.0 APO water dipping 
objective (Leica Microsystems GmbH, Wetzlar, Germany). A 488 nm Argon and a 
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633 nm HeNe laser were used to record two-dimensional Z-stack images, resulting 
in 300-600 images per sample with a 0.72x0.72 µm pixel size and 1-3 µm step-size. 
Thereafter, Z-stacks were de-convoluted using a theoretical point-spread-function 
(PSF) in the Huygens Professional software (SVI, Hilversum, The Netherlands). 
Image processing and 3D rendering was performed with Fiji (ImageJ 1.49s) and 
Amira (version 5.5.0, ThermoFisher Scientific, Waltham, USA) software. For 3D 
renderings as depicted in this manuscript, Z-stacks were loaded in Amira after which 
we applied combined surface rendering and volume rendering with standard 
settings.51 Total Z-stacks and 3D renderings were 739 µm by 739 µm in size with a 
500 to 1000 µm depth. 
 
Pathological evaluation and statistical analysis 
Visual analysis and tubule measurement was done on Z-stacks as well as 
on corresponding rendered 3D reconstructions. Benign and pre-cancerous lesions 
could be identified by Keratin 8/18 positive luminal cells surrounded by Keratin 5 
positive basal cells, whereas prostate cancer lacked the basal cell layer. The outer 
edges of the epithelial lesions were measured in 3 to 5 separate slides per image 
and 3 to 10 individual epithelial structures per slide, depending on the lesion. This 
resulted in 15-50 measurements per tissue sample. Glandular diameters were 
calculated as the average of all measurements for that lesion. Mean diameters were 
compared with a student’s T-test using the Statistical Package for Social Sciences 
(SPSS, version 24, IBM, Chicago, USA). 
 
 
Figure 1. Workflow for 3D imaging of formalin-fixed, paraffin-embedded tissues. i) Tissue selection on 
HE slides, ii) tissue punching from corresponding blocks, in which the HE slide was directly adjacent to 
the top of the cylindrical biopsy punch, iii) incubation with fluorescently labelled antibodies, iv) optical 
tissue clearing, v) fluorescent confocal imaging, vi) stacking of confocal images and visual Z-stack 
analysis, vii) image processing and 3D rendering.  
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RESULTS 
 
Peripheral and transition zone 
On routine HE slides, peripheral zone glands consist of round, oval or slightly 
irregular glands with local small intraluminal protrusions with a fibrovascular core. 
Three-dimensional imaging revealed that peripheral zone glands had an acinar 
organisation, which was composed of interconnecting blind-ending saccular tubules 
with a mean diameter of 151 µm (standard deviation (SD) 55 µm, Fig. 2A,B). These 
tubules did not show a hierarchical pattern and a clear distinction between distal 
saccular structures and more central ducts was lacking (Suppl. Video 1). The scant 
intraluminal protrusions represented finger-like structures rather than longitudinal 
plicae. The 3D architecture of transition zone glands was similar to peripheral zone 
glands, with a mean tubular diameter of 165 µm (SD 75 µm). The most prominent 
difference was the abundance of intraluminal protrusions (Fig. 2C,D, Suppl. Video 
2). Most acini were entirely surrounded by a compact sheet of Keratin 5 positive 
basal cells. However, regions of regularly spaced basal cells with slender 
interconnecting cytoplasmic sprouts were also identified, usually at tubule endings 
(Fig. 2D inset). The interconnecting saccular structures were more abundantly 
present in adenomatous hyperplastic nodules. 
 
 
 
 
 
 
 
 
Figure 2. Peripheral zone A) HE 
slide and B) 3D rendering, showing 
large saccular tubules with 
interconnections, variable width and 
continuous layer of basal cells. 
Transition zone C) HE slide and D) 
3D rendering with abundant 
presence of epithelial protrusions. 
Inset: 3D rendering of a tubule 
ending with scattered basal cells 
showing slender cytoplasmic 
interconnections. Original mag-
nifications 10x (A, C) and 20x (B, D), 
green Keratin 8/18 and red Keratin 
5 immunostaining in 3D renderings. 
Scalebars: 100 µm. 
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Atrophy 
Four different variants of prostate glandular atrophy are recognised on HE slides: 
simple atrophy, simple atrophy with cyst formation, partial atrophy and post-atrophic 
hyperplasia.68 The overall 3D glandular architecture of simple atrophy was tubular, 
emphasizing the prostatic acinar organisation of central tubules with branching and 
blind-ending tubules. The tubules had a mean diameter of 52 µm (SD 16 µm) and 
were surrounded by a continuous sheet of basal cells (Fig. 3A,B). In some cases 
connections were seen between atrophic tubules and larger glands with corpora 
amylacea (Suppl. Video 3). Cystic atrophy consisted of dilated glands with a mean 
diameter of 202 µm (SD 118 µm), significantly larger than the acini of the peripheral 
or transition zone (P<.001). Here, the overall acinar organisation was retained with 
presence of dilated saccular or tubular outpouchings from the cyst (Fig. 3C,D, Suppl. 
Video 4). In some cases, large corpora amylacea could be seen in the cystic tubules. 
Post-atrophic hyperplasia had a similar acinar organisation in which the difference 
between central and branching blind-ending tubules could be more clearly 
appreciated (Fig. 4A,B, Suppl. Video 5). Partially atrophic tubules displayed an 
acinar organisation, with basal cells typically lacking around a significant part of the 
lesion (Fig. 4C,D; Suppl. Video 6). Although four atrophic patterns have been defined 
previously on HE slides, 3D reconstruction clearly revealed an additional pattern. 
This pattern consisted of parallel large slit-like ellipsoid spaces with few 
interconnections resulting in a Golgi-like organisation (Fig. 4E,F; Suppl. Video 7). On 
HE slides this atrophic variant appeared as longitudinally sectioned tubules at the 
dorsolateral sides of the prostate. 
 
Adenosis 
On HE slides, adenosis can closely mimic Gleason score 6 prostate cancer, with 
closely packed round glands lined with slightly atypical luminal epithelial cells, often 
with intraluminal secretions and crystalloids. Three-dimensional renderings showed 
that adenosis was composed of small to medium sized tubules with a mean diameter 
of 71 µm (SD 33 µm). These tubules were smaller than transition zone gland tubules 
(P<.001) and discontinuously covered with basal cell clusters. The tubules were 
branching to such extent that no obvious acinar organisation could be appreciated 
(Fig. 5A,B, Suppl. Video 8). For comparison we have included a sample of Gleason 
score 6 prostate adenocarcinoma consisting of tubules with rare interconnections. 
These formed a disorganised network composed of luminal cells only and had no 
basal cell layer (Fig. 5C,D). For a complete and comprehensive description of the 
3D architecture of prostate adenocarcinoma growth patterns, we refer to our 
previous study.69 
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Figure 3. Simple atrophy A) HE 
slide and B) 3D rendering with acini 
of short saccular tubules (arrows) 
interconnecting with a dilated gland 
filled with corpora amylacea. Cystic 
atrophy C) HE slide and D) 3D 
rendering with large dilated glands 
in connection with adjacent glands, 
represented by dark oval openings. 
Original magnifications 20x, green 
Keratin 8/18 and red Keratin 5 
immunostaining in 3D renderings. 
Scalebars:100 µm. 
 
 
 
Figure 4. Post-atrophic hyperplasia A) HE slide and B) 3D rendering with an acinus of short saccular 
tubules. Partial atrophy C) HE slide and D) 3D rendering with an irregular acinus of short tubules with 
large areas lacking a basal cell layer (arrows). Golgi-like atrophy D) HE slide and F) 3D rendering, showing 
parallel longitudinal ellipsoid slit-like structures in an arrangement that resembles the Golgi apparatus. 
Original magnifications 10x (A,C,E) or 20x (B,D,F), green Keratin 8/18 and red Keratin 5 immunostaining 
in 3D renderings. Scalebars: 100 µm. 
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High-grade prostate intraepithelial neoplasia  
On 3D imaging, high-grade prostate intraepithelial neoplasia retained an acinar 
organisation with short-tubular and saccular outpouchings of 171 µm (SD 76 µm). 
The diameter of these structures was not statistically different from peripheral or 
transition zone glands (P=.072). Most acini were lined with a compact sheet of basal 
cells, however there were only scattered basal cells present in some regions. 
Papillary intraluminal finger-like protrusions lined with luminal cells were abundant 
(Fig. 6A,B). High-grade prostate intraepithelial neoplasia was connecting to adjacent 
pre-existent glands in 3D reconstructions (Suppl. Video 9). 
 
Intraductal carcinoma  
Intraductal carcinoma of the prostate predominantly consists of malignant cribriform 
or solid epithelial proliferations spanning the entire lumen of dilated pre-existent 
glands on HE slides. Three-dimensional rendering revealed an intact distended 
acinar architecture of pre-existent glands with a mean diameter of 153 µm (SD 92 
µm), filled with a solid or cribriform mass of luminal epithelial cells. In cribriform 
lesions, lumens were either small spheroid, ellipsoid or complex interconnecting 
spaces with rounded or sharp endings (Fig. 6C,D, Suppl. Video 10). While intraductal 
carcinoma is generally larger than high-grade prostate intraepithelial neoplasia, we 
selected relatively small lesions for 3D visualisation because of confocal field view 
limitations. The most prominent difference with high-grade prostate intraepithelial 
neoplasia was the presence of lumen-spanning epithelial proliferations.  
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Figure 5. Adenosis A) HE slide and 
B) 3D rendering with tubular 
architecture, lacking a clear 
branching acinar structure. Gleason 
grade 3 prostate cancer C) HE slide 
and D) 3D rendering displaying a 
network of interconnecting tubules. 
Original magnifications 20x, green 
Keratin 8/18 and red Keratin 5 
immunostaining in 3D renderings. 
Scalebars:100 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. High-grade PIN A) HE 
slide and B) 3D rendering with 
saccular architecture and abundant 
papillary protrusions (arrow). 
Intraductal carcinoma of the 
prostate C) HE slide and D) 3D 
rendering with gland spanning 
liminal epithelial proliferation with 
irregular interconnecting luminal 
spaces. Original magnifications 10x 
(A,C) or 20x (B,D), green Keratin 
8/18 and red Keratin 5 
immunostaining in 3D renderings. 
Scalebars: 100 µm. 
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DISCUSSION 
 
In this study we provided a comprehensive overview of the 3D architecture of 
common benign prostate epithelial lesions which might mimic prostate cancer on HE 
slides. We demonstrated that peripheral and transition zone glands have an acinar 
organisation, with interconnecting saccular blind-ended tubules without clear 
hierarchical arrangement. This basic acinar organisation was retained in 
adenomatous hyperplasia and high-grade prostate intraepithelial neoplasia and was 
emphasised in atrophy. We were able to identify a novel atrophic variant by 3D 
microscopy, consisting of large flat ellipsoid spaces with a Golgi-like appearance 
parallel to the prostate dorsolateral capsule. This atrophic variant showed 
longitudinally sectioned glands on HE slides, which were located in the peripheral 
zone of the prostate. Interestingly, adenosis was the only variant showing a tubular 
instead of an acinar organisation, closely mimicking Gleason score 6 prostate 
cancer.  
The differential diagnoses of prostate cancer, including atrophy, adenosis 
and prostate intraepithelial neoplasia, have been described extensively in various 
studies.70-72 Although their histopathological and immunohistochemical features are 
well known, little is known about the underlying 3D architecture of these benign 
mimickers.73, 74 Benign and malignant prostate lesions can show overlapping 
morphological features on HE slides. However, we found that the 3D architecture of 
most benign epithelial lesions was entirely different.67, 69 For instance, simple and 
partial atrophy might closely resemble on HE and immune-stained slides, showing 
partial loss of basal cells.65 However, their 3D structure showed that these lesions 
clearly retain an acinar organisation, which is disrupted in prostate cancer.67 
Simple atrophy, partial atrophy and post-atrophic hyperplasia most clearly 
revealed the basic acinar organisation of the prostate, showing branching of a central 
tubule into small blind-ended tubules. Peripheral and transition zone glands were 
organised in an acinar fashion as well, however this was less obvious owing to the 
larger size of these glands and to the presence of papillary protrusions. Atrophic 
tubules were sometimes connected to slightly distended glands with numerous 
corpora amylacea, suggesting glandular obstruction as cause of cystic atrophy. 
Importantly, we found the presence of large slit-like atrophic glands with a Golgi-like 
3D organisation, which to our knowledge has not been reported before. We 
hypothesise that these structures are the result of compression of pre-existent 
glands, for instance by benign hyperplastic nodules. However, the dynamic 
pathophysiology of these benign glandular lesions remains to be elucidated. 
Adenosis was the only lesion in this study that showed a 3D architecture 
with non-hierarchical interconnecting tubules, reminiscent of Gleason score 6. While 
most other prostatic lesions could be discriminated from prostate cancer by their 3D 
organisation, presence of basal cells was the only distinguishing feature in adenosis. 
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The similarity between the 3D growth of adenosis and prostate cancer Gleason 
grade 3 raises the question of whether adenosis and prostate cancer are related. 
Despite detection of rare molecular aberrations in adenosis, it is different from 
prostate cancer at the molecular level, for instance there is complete absence of 
TMPRSS2:ERG fusions in adenosis.75-78 Although adenosis is not a malignant 
proliferation, it may share aberrant activation of molecular pathways involved in 3D 
glandular expansion with low-grade prostate cancer. 
A strong point of the current study was the use of intact tissue samples from 
archival prostate specimens. This facilitated selection of specific regions-of-interest 
for 3D renderings. Imaging of small intact tissue samples prevents alignment 
artefacts that could occur when using many consecutively cut and stacked slides. 
However, use of fluorescently labelled antibodies to distinguish between luminal and 
basal epithelial cells restricts the potential sample volume to be visualised owing to 
limited antibody penetration, especially in compact glandular structures. Therefore, 
3D imaging of larger areas was not feasible using the current protocol which is a 
disadvantage as compared to other 3D imaging techniques such as registration of 
serial sections.31 In addition, image analysis is time consuming, and this meant that 
we were able to evaluate only a limited number of tissue samples, not covering the 
entire range of benign prostate epithelial lesions. 
In conclusion, long-distance confocal microscopy and optical tissue clearing 
can be used to comprehensively visualise the unique 3D architecture of benign 
prostate epithelial lesions. While various lesions might mimic malignancy on routine 
tissue slides, we found that their 3D architecture is mostly entirely different from 
prostate cancer. Finally, 3D imaging can be helpful in elucidating the 
pathophysiology of benign prostate glandular lesions. 
 
Supplementary Videos may be found in the online version of this article. 
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architectural subgroups of prostate cancer growth 
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ABSTRACT 
 
Aims: The Gleason score is one of the most important parameters for therapeutic 
decision-making in prostate cancer patients. Gleason growth patterns are defined by 
their histological features on 4-5 µm cross-sections and little is known about their 
three-dimensional architecture. Our objective was to characterise the three-
dimensional architecture of prostate cancer growth patterns.  
 
Methods and results: Intact tissue punches (n=46) of representative Gleason growth 
patterns from radical prostatectomy specimens were fluorescently stained with 
antibodies targeting Keratin 8/18 and Keratin 5 for detection of luminal and basal 
epithelial cells, respectively. Punches were optically cleared in benzyl alcohol: benzyl 
benzoate and imaged using a confocal laser scanning microscope up to a depth of 
500 µm.: Gleason pattern 3, poorly formed pattern 4 and cords pattern 5 all formed 
a continuum of interconnecting tubules where the diameter of the structures and the 
lumen size decreased with higher grade. In fused pattern 4 the interconnections 
between the tubules were markedly closer together. In these patterns all tumour cells 
were in direct contact with the surrounding stroma. In contrast, cribriform Gleason 
pattern 4 and solid pattern 5 demonstrated a three-dimensional continuum of 
contiguous tumour cells, where the vast majority of cells had no contact with the 
surrounding stroma. Transitions between cribriform pattern 4 and solid pattern 5 
were seen. There was a decrease in the number and size of inter-cellular lumens 
from cribriform to solid growth pattern. Glomeruloid pattern 4 formed an intermediate 
structure consisting of a tubular network with intra-luminal epithelial protrusions close 
to tubule splitting points. 
 
Conclusions: In conclusion, three-dimensional microscopy revealed two major 
architectural subgroups of prostate cancer growth patterns: 1) a tubular 
interconnecting network including Gleason pattern 3, poorly formed and fused 
Gleason pattern 4 and cords Gleason pattern 5, and 2) serpentine contiguous 
epithelial proliferations including cribriform Gleason pattern 4 and solid Gleason 
pattern 5.   
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INTRODUCTION 
 
The Gleason score is one of the most important parameters for therapeutic 
decision making in men with prostate cancer and is entirely based on tumour growth 
patterns.36, 79 Tumour heterogeneity is recognised by adding the two most common 
Gleason patterns in radical prostatectomy specimens. Gleason patterns 1, 2 and 3 
prostate cancers are composed of well-delineated malignant glands, and distinction 
of these patterns is putatively of no clinical significance.80 Gleason pattern 4 tumours 
consist of poorly formed, fused, cribriform or glomeruloid structures. Tumour growth 
in cords, single cells or solid fields, or the presence of comedonecrosis, 
characterises Gleason pattern 5. Whereas men with Gleason score 6 (ISUP group 
1) prostate cancer are often eligible for surveillance, active treatment is usually 
offered to patients with Gleason score ≥ 7 (ISUP group ≥ 2).57 
Although individual growth patterns within Gleason pattern 4 and 5 are not 
routinely mentioned in pathology reports, numerous studies have demonstrated 
poorer outcome when cribriform growth is present.9, 81-84 Cribriform growth in radical 
prostatectomies and diagnostic biopsies has been associated with more post-
operative biochemical recurrence and disease-specific death in ISUP group ≥ 2 
prostate cancer patients.83 On the other hand, ISUP group 2 patients with 
glomeruloid architecture may have better outcome than those without this pattern.9 
Consideration of individual growth patterns may therefore have added value for 
therapeutic stratification of ISUP group 2 prostate cancer patients. 
A major limitation of the Gleason grading system is the substantial inter-
observer variability.85-87 Amongst others, Egevad et al. found that among 337 
European pathologists only 56% agreement was achieved between expert 
consensus and participants’ score.88 Inter-observer variability in Gleason grading 
occurs predominantly in assessment of poorly formed and fused growth patterns.9, 
37, 81, 83, 87 In particular small glands with sporadic lumen formation may be interpreted 
as tangentially sectioned Gleason pattern 3, poorly formed pattern 4 or cords pattern 
5. Inter-observer variability significantly affects clinical decision-making since 
distinction of ISUP group 1 prostate cancer from higher grades is an important 
threshold for active surveillance and treatment.57 
Diagnostic criteria for histopathological grading of prostate cancer are 
entirely based on tumour features on routine 4-5 µm tissue sections. Very little is 
known about the underlying three-dimensional (3D) architecture of Gleason growth 
patterns. Serial sectioning and scanning of many tissue sections has given some 
insight into 3D tumour architecture, however, this is costly, time-consuming and 
susceptible to artefacts. In contrast, optical tissue clearing allows for sensitive 
fluorescent imaging of whole tissue specimens without physical sectioning.21, 27, 52, 89  
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We have already demonstrated the feasibility of this technique for 3D visualisation 
of formalin-fixed, paraffin-embedded prostate tissues up to a depth of 800 µm.67 The 
objective of the current study was to characterise and provide a comprehensive 
overview of the 3D architecture of prostate cancer growth patterns.  
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MATERIALS AND METHODS 
 
Case selection  
Archival formalin-fixed paraffin-embedded radical prostatectomy specimens from 
patients who had undergone radical prostatectomy for prostate cancer at the 
Erasmus Medical Centre between 2012 and 2017 were included. Specimens were 
fixed in neutral-buffered formalin, transversely cut in 4 mm slices and entirely 
embedded for histopathologic evaluation. The mean age at operation was 66 years 
(SD 6.8 years). Regions of interest for 3D imaging were indicated on hematoxylin & 
eosin (HE) stained slides by a urogenital pathologist. In total, 46 tumour areas from 
35 patients were selected for analysis, including Gleason pattern 3 (n=8), poorly 
formed (n=6), fused (n=6), glomeruloid (n=10) and cribriform (n=6) Gleason pattern 
4, and cords (n=7) and solid fields (n=3) Gleason pattern 5. Three normal peripheral 
zone areas were included to serve as a reference. The use of tissue samples for 
scientific purposes was approved by the institutional Medical Research Ethics 
Committee (MEC-2011-295, MEC-2011-296) and was in accordance with the “Code 
for Proper Secondary Use of Human Tissue in The Netherlands” as developed by 
the Dutch Federation of Medical Scientific Societies (FMWV, version 2002, update 
2011). 
 
Immunofluorescent staining and optical clearing 
Tissue punches from the areas with the selected growth patterns were taken from 
the corresponding paraffin blocks using a 500 µm diameter needle (Estigen Tissue 
Scuebcem, Tartu, Estonia) resulting in 3-4 mm long cylindrical tissue cores with a 
diameter of 500 µm. Immunofluorescent staining and optical clearing was carried out 
according to an adapted iDISCO protocol as described previously (Suppl. table 1).49, 
67 Briefly, punches were dewaxed after which auto-fluorescence was blocked 
overnight. Subsequently, punches were gradually rehydrated and incubated with 
primary Keratin 5 and Keratin 8/18 antibodies (1:150; EP1601Y; Abcam, Cambridge, 
UK and 1:75; MS-743; Immunologic, Duiven, The Netherlands) and secondary 
fluorescent Alexa-514 and Alexa-647 labelled antibodies (1:200; Life Technologies, 
Bleiswijk, The Netherlands). In order to visualise subtle connective tissue cores 
within fused Gleason pattern 4, these samples were additionally stained with 
Fibronectin (FN1; 1:50; ab2413, Abcam, Cambridge, United Kingdom) and 
secondary Alexa-647 antibodies. Tissue was again dehydrated in methanol and 
subsequently optically cleared in benzyl alcohol: benzyl benzoate. Samples were 
then stored at 4°C in the dark until imaging.  
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Sample imaging 
Fluorescently stained punches were imaged with an upright Leica SP5 confocal 
microscope equipped with a 1.95 mm working distance 20x NA1.0 APO water 
dipping objective (Leica Microsystems GmbH, Wetzlar, Germany). Two-dimensional 
Z-stack images were recorded using a 488 nm Argon and a 633 nm HeNe laser with 
a 0.72x0.72 µm pixel size and 1-3 µm step-size, resulting in 300-600 images per 
sample. Huygens Professional software (SVI, Hilversum, The Netherlands) with a 
theoretical point-spread-function (PSF) was used for de-convolution of the Z-stacks, 
whereas 3D rendering and image measurements were performed with Fiji (ImageJ 
1.49s) and Amira (version 5.5.0, ThermoFisher Scientific, Waltham, USA) 
software.51 Z-stacks were loaded in Amira, after which we applied combined surface 
and volume rendering with standard settings. The total size of the Z-stacks and 3D 
renderings was 739 by 739 µm with a depth of 500 µm. Reference HE slides were 
positioned at a vertical side of the 3D renderings, but are not directly continuous with 
the depicted areas in each case, depending on the site of imaging in the 3-4 mm 
long cylindrical core. 
 
Pathological evaluation and statistical analysis 
Both consecutive Z-stacks and 3D rendered images were investigated. Pre-existent 
benign prostate glandular structures were identified by Keratin 8/18 positive luminal 
cells surrounded by Keratin 5 positive basal cells. Prostate cancer structures were 
recognised by architecturally disorganised Keratin 8/18 positive epithelial structures 
without a basal cell layer. Tubular blind-ending tips were identified by detailed 
analysis of both Z-stacks and 3D renderings, and could be well distinguished from 
transversely sectioned tubules at the border of the tissue samples. In each of the 
tissue specimens, the outer edges of the epithelial structures were measured in 3 to 
5 consecutive 2D slides per image and 3 to 10 individual epithelial structures per 
slide, depending on the growth pattern. This resulted in 12-50 measurements per 
tissue sample. Statistics were performed with a student’s T-test using the Statistical 
Package for Social Sciences (SPSS, version 24, IBM, Chicago, USA). Original 
magnifications of HEs and 3D renderings 20x, with green Keratin 8/18 and red 
Keratin 5 staining in 3D renderings.  
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RESULTS 
 
Benign epithelial glands 
Benign peripheral zone glands had an acinar organisation composed of 
interconnecting saccules with variable intraluminal papillary protrusions. Benign 
glands were composed of an inner Keratin 8/18 positive luminal cell layer and an 
outer flat Keratin 5 positive layer of basal cells (Fig. 1A,B; Suppl. Video 1). In all 
cases malignant epithelial structures could easily be distinguished from pre-existent 
benign glands by their architectural organisation and lack of basal cells (Fig. 1C,D).  
 
 
 
 
 
 
 
 
Figure 1. Peripheral zone A) HE 
slide and B) 3D rendering, showing 
interconnecting saccules of variable 
width containing intraluminal 
papillary protrusions and surrounded 
by a continuous Keratin 5 positive 
basal cell layer (red). C) HE slide and 
D) 3D rendering of pre-existent 
benign glands surrounded by basal 
cells (upper left) and irregular 
malignant epithelial structures 
without basal cell layer (lower). 
Original magnifications 20x, green 
Keratin 8/18 and red Keratin 5 
immunostaining in 3D renderings. 
Scalebars: 100 µm. 
 
 
Gleason pattern 3 
Gleason pattern 3 prostate cancer was composed of round to slightly oval, well-
delineated curving tubules with a mean diameter of 45 µm (SD 12 µm) with regular 
interconnections (Fig. 2A,B; Suppl. Video 2). All malignant epithelial cells had 
contact with surrounding stroma. We did not find any specific tubular orientation 
along the cranial-caudal, transverse or sagittal axis of the prostate. Blind-ending 
tubules were present sporadically and showed no specific location within the tubular 
network. 
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Gleason pattern 4 
Poorly formed glands 
Poorly formed Gleason pattern 4 glands were represented by small round tubules 
with a significantly smaller average diameter than Gleason pattern 3 tubules (24 µm, 
SD 7 µm; P<.001). Poorly formed glands showed more frequent interconnections 
and blind-endings than Gleason pattern 3 tubules (Fig. 2C,D). Regularly, we 
observed transitions between poorly formed Gleason pattern 4 glands and Gleason 
pattern 3 tubules (Fig. 2E; Suppl. Video 3). 
 
Fused glands 
Fused Gleason pattern 4 glands consisted of round to oval tubules with a diameter 
of 68 µm (SD 18 µm), slightly larger than Gleason pattern 3 tubules (P<.001). The 
hallmark of the fused pattern was the presence of abundant interconnections 
between the tubules, which occurred markedly closer together than in the 
aforementioned patterns (Fig. 3A,B). On HE slides fused Gleason pattern 4 can 
closely resemble cribriform architecture.87, 88 Here 3D microscopy however revealed 
subtle intervening fibrovascular tissue in between and around all malignant tubules, 
revealing that all malignant cells had contact with surrounding stroma (Suppl. Video 
4). 
 
Cribriform fields 
Cribriform Gleason pattern 4 was characterised by fields of contiguous epithelial 
tumour cells with a mean diameter of 151 µm (SD 68 µm). The vast majority of 
tumour cells did not have any contact with the surrounding stroma, in contrast with 
the patterns described previously. Three-dimensionally, this pattern showed a 
variable number of spherical, ellipsoid, slit-like or irregular interconnecting inter-
cellular lumens (Fig. 3C,D). Adjacent cribriform fields with intervening stroma on HE 
slides represented continuously curving irregular serpentine structures on 3D 
renderings (Suppl. Video 5). We did not observe any transition between cribriform 
fields and aforementioned tubular structures in our cohort. 
 
 
51 
 
 
Figure 2. Gleason pattern 3 A) HE slide and B) 3D rendering showing a tubular network with 
interconnections (arrows) and blind-endings (arrowheads). Poorly formed Gleason pattern 4 C) HE slide 
and D) 3D rendering of small-sized interconnecting tubules with blind-endings (arrowheads). E) Well-
delineated Gleason pattern 3 tubules (arrows) were directly connected to and continuous with poorly 
formed Gleason pattern 4 structures (arrowheads). Original magnifications 20x, green Keratin 8/18 and 
red Keratin 5 immunostaining in 3D renderings. Scalebars: 100 µm. 
 
 
 
 
 
 
Figure 3. Fused Gleason pattern 4 
A) HE slide with subtle fibrovascular 
cores (arrows) and B) 3D 
reconstruction revealing frequently 
interconnecting tubules. Cribriform 
Gleason pattern 4 C) HE slide and D) 
3D rendering of cribriform fields 
displaying contiguous epithelial cells 
with spherical and ellipsoid inter-
cellular lumens. The majority of 
tumour cells do not contact with the 
surrounding stroma. The cribriform 
areas formed serpentine structures 
with variably sized interconnections 
(arrows). Original magnifications 
20x, green Keratin 8/18 and red 
Fibronectin (B) immunostaining in 3D 
renderings. Scalebars: 100 µm. 
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Glomeruloid glands 
In two-dimensional cross-sections glomeruloid Gleason pattern 4 structures 
resemble renal glomeruli and are characterised by dilated glands with round 
protrusions of malignant epithelial cells (Fig. 4A,B). On 3D renderings, these 
glomeruloid structures were present within an interconnecting network of tubules, 
which had a mean diameter of 65 µm (SD 19 µm) reminiscent of Gleason pattern 3 
glands but with larger tubule diameters (P<.001). Two different glomeruloid 
structures could be distinguished using 3D microscopy. The first type were nodular 
epithelial glomeruloid proliferations which connected to the tumour cells lining the 
tubule on one side, but did not make contact with the tubular lining on the opposite 
side or the surrounding stroma. These protrusions often occurred at tubular 
branching points (Suppl. Video 6). The second type showed presence of subtle 
fibrovascular cores on the HE slides, representing clusters of markedly curved 
tubules in three-dimensions. All the tumour cells within this glomeruloid variant made 
contact with the surrounding stroma. When glomeruloid structures are larger, 
distinction between glomeruloid and cribriform growth pattern on HE slides can be 
challenging (Fig. 4C).87 These larger cribriform-like structures grew similar to the first 
type of glomeruloid pattern in 3D renderings. We did not observe continuity between 
glomeruloid structures and the cribriform pattern.  
 
Gleason pattern 5 
Cords and single cells 
On HE slides, Gleason pattern 5 cords consist of one or two-layered cords of cells 
without distinctive lumens (Fig. 5A). In 3D, cords and single cell structures formed a 
continuous meshwork consisting of one or two cell-layers with extensive branching 
and interconnections. The average diameter of these cords was 15 µm (SD 7 µm; 
Fig. 5B), significantly smaller than poorly formed Gleason pattern 4 (P<.001). Small 
inter-cellular lumens were observed at deeper levels of the cord pattern in the Z-
stack, indicating repetitive subtle transitions from Gleason pattern 4 poorly formed 
tubules to Gleason pattern 5 cords (Suppl. Video 7). 
 
Solid fields 
Solid fields Gleason pattern 5 are represented on hematoxylin & eosin slides as 
round or irregularly formed areas composed of tumour cells without intercellular 
lumens. Most cells do not make contact with the surrounding stroma (Fig. 5C). 3D 
reconstruction revealed that the solid fields represented round to ellipsoid irregular 
serpentine structures with an average diameter of 185 µm (SD 78 µm), 
interconnecting and varying in width (Fig. 5D; Suppl. Video 8). While intercellular 
lumens were inconspicuous on hematoxylin & eosin slides, the Z-stacks often 
showed small round and ellipsoid lumens reminiscent of cribriform Gleason pattern 
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4 at deeper levels, indicating transition between these patterns. In this cohort, we did 
not find transition between solid fields Gleason pattern 5 and tubular growth patterns.  
 
 
 
Figure 4. Glomeruloid Gleason pattern 4 A) HE slide and B) 3D rendering of small glomeruloid 
protrusions, consisting of malignant epithelial cells in contact with the epithelial tubular lining at one side 
of the tubule (arrow). C) Large glomeruloid protrusion with intercellular lumens. While this structure 
resembles cribriform architecture, the glomeruloid protrusion only makes contact with one side of the 
tubule. Original magnifications 20x, green Keratin 8/18 and red Keratin 5 (no basal cells present) 
immunostaining in 3D renderings. Scalebars: 100 µm. 
 
 
Figure 5. Gleason pattern 5 cords A) HE slide and B) 3D rendering with interconnecting cords consisting 
of one or two tumour cells without lumens. Solid Gleason pattern 5 C) HE slide and D) 3D rendering 
showing solid structures with variably sized interconnections (arrows). E) Transition from cribriform 
Gleason pattern 4 (left side) with multiple lumens (arrows) to solid Gleason pattern 5 (right side) lacking 
lumen formation (arrowhead).  Original magnifications 20x, green Keratin 8/18 and red Keratin 5 (no basal 
cells present) immunostaining in 3D renderings. Scalebars: 100 µm.
54 
 
DISCUSSION 
 
In the current study we provided a comprehensive overview of the three-dimensional 
architecture of prostate cancer growth patterns and revealed two architecturally 
different growth pattern subgroups. The first subgroup consisted of a tubular network 
where the vast majority of the tumour cells made direct contact with the surrounding 
stroma. We demonstrated that Gleason pattern 3 glands formed a network of 
regularly interconnecting tubules. In poorly formed Gleason pattern 4 the network 
consisted of smaller sized tubules, and in fused Gleason pattern 4 the tubules 
showed frequent and closely spaced interconnections. In glomeruloid Gleason 
pattern 4 intra-luminal epithelial protrusions occurred within the tubular network, 
close to tubular branching points. Cords Gleason pattern 5 represented a network 
structure with frequent interconnections without lumens. The second subgroup was 
characterised by contiguous tumour cell proliferations where the vast majority of 
tumour cells did not make contact with the surrounding stroma, consisting of 
cribriform Gleason pattern 4 and solid pattern 5. This subgroup represented irregular 
serpentine structures of contiguous tumour cells with a decrease in frequency and 
size of intercellular lumens from cribriform to solid pattern.  
An important advantage of 3D imaging is the visualisation of morphological 
transitions and continuity of growth patterns which can generally not be appreciated 
in routine 2D sections. Until now only a few studies have aimed to reconstruct 
prostate cancer growth patterns in three-dimensions, using sectioning and alignment 
of numerous sequential slides.27, 29-31, 44, 90 For instance, Boag et al. used this method 
on 5 different cases to generate 3D renderings, showing interconnections between 
Gleason pattern 3 and pattern 4 glands.30 Similarly, Tolkach et al. demonstrated 
continuity between Gleason pattern 3 and pattern 4 after serial sectioning and 3D 
rendering of one ISUP group 2 case.31 Apart from being laborious, stacking of 
sequentially cut slides is prone to tissue malformation and registration artefacts. In 
contrast, fluorescent staining, tissue clearing and long-distance confocal scanning 
microscopy is performed on intact tissue samples without tissue sectioning, thus 
preventing alignment artefacts. It is also less laborious, although specialised 
microscopic equipment is required.67 Our finding of three-dimensional continuity 
between Gleason patterns 3 and 4 is in line with the aforementioned studies, even 
though different methods were applied.  
The most important observation of this study was that we identified two 
architecturally different growth pattern subgroups. Firstly, there are interconnecting 
tubular structures, consisting of Gleason pattern 3, poorly formed and fused Gleason 
pattern 4 and cords Gleason pattern 5. These patterns have variable tubule 
diameters, interconnection frequencies and lumen formations, but the vast majority 
of the tumour cells make direct contact with the surrounding stroma. In our cohort 
we observed frequent transitions between these growth patterns. While poorly 
formed glands had smaller sized tubules than Gleason pattern 3, no clear cut-off 
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could be made between these patterns with respect to tubule diameter, number of 
interconnections or luminal size. Similarly, 3D spatial transitions between poorly 
formed Gleason pattern 4 and Gleason pattern 5 cords made strict delineation of 
these patterns impossible. The increased number of interconnections in fused 
Gleason pattern 4 was only arbitrarily distinguished from branching Gleason pattern 
3 tubules. The three-dimensional continuity of these patterns is reflected by the 
substantial inter-observer variability in daily pathology practice. Distinguishing on the 
one hand tangentially sectioned Gleason pattern 3 glands from poorly formed and 
fused Gleason pattern 4 glands, and on the other hand poorly formed Gleason 
pattern 4 glands from Gleason pattern 5 cords on hematoxylin & eosin slides are the 
principal areas of difficulty.37, 43, 87, 91 Secondly, there are serpentine compact 
irregular epithelial proliferations, consisting of cribriform Gleason pattern 4 and solid 
Gleason pattern 5, with decreasing inter-epithelial lumen sizes and frequencies. Both 
patterns have in common that the vast majority of tumour cells are contiguous and 
do not make contact with the surrounding stroma. Although we did not include 
comedonecrosis in this study, routine diagnostic slides reveal that comedonecrosis 
predominantly occurs in a background of cribriform and solid structures. We found 
transitions between cribriform Gleason pattern 4 and solid Gleason pattern 5 but did 
not observe transitions between these patterns and the aforementioned tubular 
growth pattern subgroup.  
The inter-observer agreement of cribriform Gleason pattern 4 is excellent. 
The only variability there is occurs in the distinction with complex fused and large 
glomeruloid patterns.87 Of interest, our 3D images showed that although complex 
fused Gleason pattern 4 glands might resemble cribriform Gleason grade 4 
structures on hematoxylin & eosin slides, scattered subtle intra-lesion fibrovascular 
cores were present in complex fused Gleason pattern 4 glands as a distinguishing 
feature. On hematoxylin & eosin slides, glomeruloid growth morphologically 
represents an intermediate pattern between tubular and cribriform growth. While 
some glomeruloid structures with subtle fibrovascular cores actually closely 
resembled fused Gleason pattern 4 glands in 3D, most glomeruloid structures did 
not contain intra-lesional connective tissue. Based on morphological resemblance 
and frequent coexistence, Lotan and Epstein hypothesised that glomeruloid pattern 
is a precursor of cribriform growth.92 However, Choy et al. found that ISUP group 2 
and 3 prostate cancer patients with glomeruloid pattern had significantly lower 
biochemical recurrence rates than those with cribriform growth.81 Our 3D 
reconstructions did not reveal continuity between glomeruloid and cribriform 
structures. Therefore, the clinical relevance of the glomeruloid pattern and its place 
as putative precursor of cribriform growth remains to be established. 
Various studies have shown that prostate cancer patients with a ISUP group 
2 tumour showing cribriform Gleason pattern 4 have a worse outcome than patients 
without this pattern. Kweldam et al. found that patients with a ISUP group 2 tumour 
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without cribriform growth on biopsy had similar metastasis-free survival and 
biochemical recurrence rates as patients with ISUP group 1 prostate cancer.9, 83 The 
adverse outcome related to cribriform growth was also present in men with ISUP 
group > 2 prostate cancer.9, 93 A putative explanation for the worse outcome of 
patients with cribriform growth pattern is the fact that cribriform architecture is 
associated with genomic instability, while non-cribriform Gleason patterns 4 are 
genomically indistinguishable from Gleason pattern 3.94-96 These clinical and 
molecular observations are in line with the two architectural subgroup hypothesis as 
raised in the current study. To the best of our knowledge there are as yet no studies 
on the clinical relevance of Gleason 5 growth patterns. Investigation into the 
prognostic value of these individual Gleason grade 5 patterns is essential for future 
tumour grading and understanding. Based on our current findings, we hypothesise 
that solid Gleason pattern 5 is likely to be associated with worse outcome than cords 
or single cells Gleason pattern 5. 
This study represents the first comprehensive three-dimensional 
characterisation of relevant prostate cancer growth patterns. Optical clearing of 
intact samples allows visualisation and investigation of tumour growth patterns 
without the need for sectioning and alignment of numerous consecutive tissue slides. 
We studied the most common prostate cancer growth patterns, but did not include 
the full spectrum of growth patterns and variants that can be encountered in daily 
practice.97, 98 While we selected unambiguous cases of the Gleason growth patterns, 
inter-observer variability might still exist, for instance in labelling as either poorly 
formed or fused Gleason pattern 4.87, 88 Another disadvantage of 3D pathology is the 
descriptive terminology that is used for reporting. Three-dimensional imaging of 
prostate cancer, however, allows for objective geometrical modelling in a 3D matrix. 
Finally, while we identified two 3D growth pattern subgroups with glomeruloid 
architecture as an intermediate structure, the differences between these subgroups 
on the clinical and molecular level remain to be investigated. 
In conclusion, this study gives a comprehensive overview of the 3D 
architecture of prostate cancer growth patterns. We show the existence of two major 
architectural growth patterns subgroups: 1) a tubular interconnecting network of 
tumour cells in direct contact with adjacent stroma, with a variable gland and lumen 
size, including Gleason pattern 3, poorly formed and fused Gleason pattern 4 and 
cords Gleason pattern 5, and 2) serpentine contiguous epithelial proliferations where 
the majority of tumour cells do not make contact with adjacent stroma and with 
variable inter-epithelial lumen frequency, including cribriform Gleason pattern 4 and 
solid Gleason pattern 5. Insight into tumour growth patterns facilitates 
comprehension of prostate cancer behaviour and biology beyond current Gleason 
grading. 
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Supplementary Tables and Videos may be found in the online version of this 
article. 
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Concordance of cribriform architecture in matched  
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ABSTRACT 
Aims: Invasive cribriform and/or intraductal carcinoma have been identified as 
independent adverse parameters for prostate cancer outcome. Little is known on 
biopsy undersampling of cribriform architecture. Our aim was to determine the extent 
of cribriform architecture undersampling and to find predictive factors for identifying 
false cribriform negative cases.  
 
Methods and results: We reviewed 186 matched prostate biopsies and radical 
prostatectomy specimens. Of 97 biopsy Grade Group 2 (Gleason score 3+4=7) 
patients, 22 (23%) had true cribriform negative (TN), 39 (40%) false negative (FN) 
and 36 (37%) true positive (TP) biopsies. Patients with FN biopsies had higher albeit 
not statistically significant (P=.06) median PSA levels than patients with TP biopsies 
(12 versus 8 ng/ml). A PI-RADS 5 lesion was present in 9/16 (54%) FN and 3/11 
(27%) TN biopsies (P=.05). Positive biopsy rate (P=.47), percentage Gleason 
pattern 4 (P=.55) and glomeruloid architecture (P=1.0) were not different. Logistic 
regression identified PSA as independent predictor (Odds Ratio 3.5; 95% 
Confidence Interval 1.2-9.4, P=.02) for cribriform architecture on radical 
prostatectomy but PI-RADS score not. The FN rate for large cribriform architecture 
at radical prostatectomy was 27%, which was lower than for any cribriform 
architecture (P=.01). During follow-up (median 27 months), biochemical recurrence-
free survival of patients with TP biopsies was significantly shorter than of those with 
FN biopsies (P=.03). 
 
Conclusions: In conclusion, 40% of Grade Group 2 prostate cancer biopsies were 
FN for cribriform architecture. These patients had higher PSA levels and more 
frequent PI-RADS score 5 lesions than men with TN biopsies. 
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INTRODUCTION 
Risk stratification and therapeutic decision-making in prostate cancer patients is 
affected by potential biopsy undersampling. The Gleason score is one of the most 
important parameters for predicting disease outcome and guiding individual 
treatment. Men with Gleason score 3+3=6 (International Society of Urological 
Pathology (ISUP) Grade Group 1) prostate cancer are eligible for active surveillance, 
whereas men with Gleason score ≥ 4+3=7 (Grade Group 3-5) are usually treated 
with radical prostatectomy, radiation therapy and/or hormonal therapy. The optimal 
therapeutic strategy for men with Gleason score 3+4=7 (Grade Group 2) still is a 
matter of debate. While most of these patients will undergo active treatment, 
surveillance is increasingly being considered in this subgroup. Incorporation of 
additional clinicopathological and molecular parameters might be able to support 
optimal decision-making in this large prostate cancer subpopulation. 
Grade Group 2 prostate cancer is a heterogeneous disease with variable 
architectural growth patterns and Gleason pattern 4 quantities. While individual 
growth patterns are not routinely mentioned in pathology reports, recent studies have 
shown that patients with cribriform architecture have adverse outcome as compared 
to those without.9, 99, 100 Both invasive and intraductal cribriform architecture have 
been associated with adverse clinicopathological characteristics, post-operative 
recurrence rates, metastasis and disease-specific death.82, 84, 101-103 On the other 
hand, biopsy Grade Group 2 prostate cancer patients without cribriform architecture 
have comparable disease-specific survival and post-operative biochemical 
recurrence rates as men with Grade Group 1 disease.9, 83 Quantification of Gleason 
pattern 4 can further add in risk stratification since post-operative biochemical 
recurrence rates increment with higher Gleason pattern 4 tumour percentage.104 
Cribriform architecture and Gleason pattern 4 quantification might therefore be 
important adjuncts in risk stratification of Grade Group 2 prostate cancer patients. 
While pathological tumour characteristics are important for clinical decision-
making, prostate biopsies are prone to undersampling. Prostate cancer is up-graded 
in up to 40% of subsequent radical prostatectomy specimens.8, 105 At present, little 
is known on the extent of undersampling in detection of cribriform architecture or 
Gleason pattern 4 percentage. The aim of our study is to determine the extent of 
undersampling for the detection of cribriform architecture in matched prostate biopsy 
and radical prostatectomy specimens, and to identify potential factors for 
discriminating true from false cribriform negative prostate biopsies. 
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MATERIALS AND METHODS 
Patient selection 
We identified 186 patients who had undergone both biopsy and subsequent radical 
prostatectomy at Erasmus MC University Medical Centre, Rotterdam, The 
Netherlands between 2010 and 2017. Biopsies were prompted by elevated Prostate 
Specific Antigen (PSA) levels or obtained in the scope of active surveillance. The 
Prostate Imaging Reporting and Data System (PI-RADS) score was annotated by 
an expert uroradiologist, when patients had received multiparametric magnetic 
resonance imaging (MRI).106 When suspicious lesions (PI-RADS 3 to 5) were visible 
on MRI, targeted MRI-ultrasound fusion biopsies were taken. Individual biopsy cores 
were enclosed in separate containers and radical prostatectomy specimens were 
completely embedded for diagnostic purposes. All slides of both biopsies and radical 
prostatectomies were available for pathologic review. This study was approved by 
the institutional Medical Research Ethics Committee (MEC-2018-1614). 
 
Pathologic evaluation 
All biopsies were reviewed by three investigators, who were blinded to clinical 
outcome and radical prostatectomy characteristics. For each biopsy core the 
following features were recorded: Gleason score, Grade Groups according to the 
WHO/ISUP 2014 guidelines, maximal single biopsy tumour length (mm), overall 
estimated percentage Gleason pattern 4 and individual tumour growth patterns.36 
Invasive cribriform Gleason pattern 4 was not distinguished from intraductal 
carcinoma because of their significant morphological overlap, which would require 
extensive immunohistochemical stainings for further discrimination.9 In case 
targeted biopsies were obtained, these were considered as separate biopsies and 
not as one single biopsy. Matching radical prostatectomy specimens were evaluated 
as described previously.101 We recorded Gleason score, Grade Group, pT-stage 
according to the AJCC TNM 8th edition, surgical margin status, percentage Gleason 
pattern 4 and individual growth patterns.107 Furthermore, we distinguished small and 
large expansive cribriform growth pattern based on a cut-off of two times the size of 
adjacent pre-existent normal glands.101 
 
Clinical follow-up 
After radical prostatectomy, clinical follow-up consisted of bi-annual, and later annual 
monitoring of serum PSA levels. Biochemical recurrence was defined as PSA levels 
≥ 0.2 ng/ml measured at two consecutive points in time, at least three months apart 
with undetectable PSA levels after operation, or as PSA increase of > 2.0 ng/ml when 
serum PSA had not declined to zero after operation. Survival was defined as time in 
months from radical prostatectomy to biochemical recurrence or last follow-up. 
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Statistical analysis 
Continuous variables with normal distribution were compared by Student’s t-test and 
One-way ANOVA analysis, those without normal distribution with the Mann-Whitney 
U test. For categorical parameters Chi-square or Fishers exact were used. 
Correlation between continuous variables was analysed using Pearson’s correlation 
coefficient. Dichotomous outcome variables were analysed using logistic regression. 
Survival was visualised by Kaplan-Meier curves. Statistics were performed using R 
version 3.2.2 (R, Vienna, Austria) and results were considered significant when the 
two-sided P-value was <.05. 
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RESULTS 
Clinicopathological characteristics 
The entire cohort consisted of 186 patients with matched biopsy and radical 
prostatectomy specimens. The mean age at time of operation was 65 years 
(interquartile range (IQR) 62-70) and the mean PSA level was 12 ng/ml (IQR 6-15). 
In total 144 (77%) patients underwent systematic biopsies, 26 (14%) received 
systematic and targeted biopsies, and 16 (9%) had targeted biopsies only. The mean 
number of biopsies taken was 9 (IQR 8-10) with 4 (IQR 3-5) biopsies containing 
adenocarcinoma, representing 49% (IQR 30-66) of the total number of biopsy cores. 
Fifty (27%) patients had overall biopsy Grade Group 1, 99 (53%) Grade Group 2, 11 
(6%) Grade Group 3, 15 (8%) Grade Group 4 and 11 (6%) Grade Group 5. 
On radical prostatectomy, 87 (47%) adenocarcinomas were pT2, 76 (41%) 
pT3a and 23 (12%) pT3b. Distribution of the Grade Groups on radical prostatectomy 
was as follows: 19 (10%) Grade Group 1, 108 (58%) Grade Group 2, 25 (14%) Grade 
Group 3, 17 (9%) Grade Group 4 and 17 (9%) Grade Group 5. Tumour up-grading 
occurred in 65 (35%) and down-grading in 14 (8%) radical prostatectomies, while 
107 (57%) cases had concordant tumour grades. Positive surgical margins were 
present in 63 (34%) patients. Eighty patients had simultaneously undergone pelvic 
lymph node dissection, of which 18 (23%) contained lymph node metastasis. The 
mean post-operative follow-up was 32 months (median 22, IQR 8-51). 
Invasive cribriform and/or intraductal carcinoma was observed in 57 (31%) 
diagnostic biopsies and in 128 (69%) radical prostatectomy specimens (Table 1). 
Cribriform architecture was present in both matched biopsy and radical 
prostatectomy specimens in 55 (30%), and absent in 56 (30%) cases. In 73 (39%) 
men cribriform architecture was observed in the radical prostatectomy specimen, but 
not in preceding biopsies. Two cases (1%) had cribriform architecture at biopsy but 
not at subsequent radical prostatectomy, which is probably due to sampling error 
and these were excluded from further analyses. Therefore, the sensitivity for 
cribriform architecture on biopsies was 43%, while specificity was 97%. Cribriform 
architecture was observed more frequently in targeted (19/40; 48%) than systematic 
biopsies (36/144; 25%, P=.01). 
 
Table 1. Prevalence of invasive cribriform and/or intraductal carcinoma (CR/IDC) in biopsies and matched 
radical prostatectomies. 
 
 
Radical prostatectomy 
Prostate biopsy  CR/IDC- CR/IDC+ 
CR/IDC- 
 56 
(30%) 73 (39%) 
CR/IDC+  2 (1%) 55 (30%) 
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Concordance of cribriform architecture in Grade Group 2 prostate cancer biopsies  
Since cribriform architecture might be most relevant for treatment decisions in 
patients with biopsy Grade Group 2 prostate cancer, we performed further analyses 
within this subgroup (n=97). Thirty six (37%) patients with biopsy Grade Group 2 
demonstrated cribriform architecture on both matched biopsy and radical 
prostatectomy specimen (true cribriform positive, CR+/CR+), while cribriform 
architecture was absent in both specimens in 22 (23%) cases (true cribriform 
negative, CR-/CR-). In 39 (40%) patients cribriform architecture was present on 
radical prostatectomy but not on preceding biopsy; these patients were considered 
as having false cribriform negative (CR-/CR+) biopsies. None of the patients with 
biopsy Grade Group 2 had cribriform architecture on biopsy while radical 
prostatectomy was negative for cribriform architecture. 
 
Identification of predictors in true and false cribriform negative Grade Group 2 
prostate cancer biopsies 
Patients with true negative biopsies were slightly younger (62 versus 65 years, 
P=.06) and had lower PSA levels (8 ng/ml versus 12 ng/ml, P=.06) than men with 
false negative biopsies, however these differences were not significant (Table 2). In 
total, 51 patients (53%) had undergone multiparametric MRI prior to biopsy. Out of 
11 patients with true negative biopsies, 3 (27%) had a PI-RADS 5 lesion as 
compared to 9/16 (56%) of false negative and 17/24 (71%) of true positive biopsy 
patients (P=.05). The number of biopsies (P=.53), percentage of positive biopsies 
(P=.47) and maximal tumour length (P=.44) were not different between true and false 
negative biopsies. Since Gleason pattern 4 percentage and glomeruloid architecture 
have both been associated with cribriform architecture, we assessed the predictive 
value of these pathologic parameters84, 92 Mean percentage of Gleason pattern 4 
was 12% (IQR 5-10%) in true negative biopsies and 11% (IQR 5-16%) in false 
negative biopsies (P=.55). There was only a weak correlation between percentage 
Gleason pattern 4 on biopsies (mean 13%, IQR 5-20%) and matched radical 
prostatectomies (mean 31%, IQR 10-40%, R2=0.093; P=.001). Glomeruloid growth 
pattern was encountered in 6/22 (27%) true negative and 11/39 (28%) false negative 
biopsies (P=1.0). 
Logistic regression analysis on cribriform negative biopsy patients showed 
that age (odds ratio (OR) 1.1, 95% confidence interval (CI) 1.0-1.3, P=.02) and PSA 
(OR 3.3, 95% CI 1.2-9.1, P=.02) were independent predictive parameters for 
presence of cribriform architecture on radical prostatectomy in multivariable analysis, 
whereas PI-RADS score, number and percentage of positive biopsies, maximal 
tumour length, presence of targeted biopsies and percentage Gleason grade 4 were 
not (Table 3).  
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Table 2. Characteristics of biopsy Grade Group 2 prostate cancer (PCa) patients stratified for true 
cribriform negative (CR-/CR-), false cribriform negative (CR-/CR+) and true cribriform positive (CR+/CR+) 
biopsies. 
 
CR-/CR- (n=22) CR-/CR+ (n=39) CR+/CR+ 
(n=36) 
P-value 
Age 62 (63, 58-65) 65 (66, 62-71) 66 (66, 62-71) .06a 
PSA 8 (8, 6-10) 12 (10, 6-17) 16 (13, 9-19) .06b 
PI-RADS score    .10c 
No MRI 11 (50%) 23 (59%) 12 (33%)  
1-2 3 (14%) 0 (0%) 0 (0%)  
3 1 (5%) 1 (3%) 2 (6%)  
4 4 (18%) 6 (15%) 5 (14%)  
5 3 (14%) 9 (23%) 17 (47%)  
Number of biopsies 9 (9, 8-10) 8 (8, 7-10) 10 (10, 8-12) .53d 
Number PCa positive biopsies 4 (3, 2-6) 4 (4, 3-5) 6 (5, 4-8) .64d 
Percentage PCa positive biopsies 47 (38, 25-71) 52 (50, 31-73) 59 (61, 40-76) .47d 
Maximal tumour length (mm) 7 (7, 5-8) 8 (7, 5-10) 9 (10, 7-12) .44d 
Percentage Gleason pattern 4 12 (8, 5-10) 11 (8, 5-16) 17 (15, 7-23) .55a 
Presence of glomeruloid growth 6 (27%) 11 (28%) 12 (33%) 1.0e 
 
Presence of large cribriform growth 0 6 (15%) 16 (44%) N/A 
Presence of targeted biopsies 2 (9%) 8 (20%) 13 (36%) .30e 
ISUP grade on radical 
prostatectomy    
.01e 
1 2 (9%) 1 (3%) 1 (3%) 
 
2 18 (82%) 29 (74%) 26 (72%) 
 
3 0 (0%) 8 (20%) 7 (19%) 
 
4 0 (0%) 1 (3%) 1 (3%) 
 
5 2 (9%) 0 (0%) 1 (3%) 
 
Positive surgical margins 8 (36%) 12 (31%) 12 (33%) .78c 
pT stage (TNM 8th ) 
   
.66c 
2 11 (50%) 15 (38%) 17 (47%) 
 
3a 10 (45%) 20 (51%) 12 (33%) 
 
3b 1 (5%) 4 (11%) 7 (20%) 
 
Biochemical recurrence 2 (9%) 6 (15%) 13 (36%) .69e 
Metastasis 0 (0%) 1 (3%) 4 (11%) N/A 
Mean (median, IQR) or n (%). a Wilcox-test, b t-test (log2 values were used for this test), c Chi-square 
(χ2), d One-Way Anova, e Fisher test. P-values resemble comparison between CR-/CR- and CR-/CR+. 
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Comparison of false negative and true cribriform positive Grade Group 2 biopsies 
PSA levels of men with true positive biopsies were slightly higher than of those with 
false negative biopsies, but this was not statistically significant (16 ng/ml versus 12 
ng/ml, P=.13). Patients with true positive biopsies had a significantly higher total 
number of biopsies (10 versus 8, P=.02) and number of tumour positive biopsies (6 
versus 4, P=.001), however no differences were seen in percentage positive biopsies 
(59% versus 52%, P=.19) when compared to patients with false negative biopsies. 
Percentage Gleason pattern 4 was higher in patients with cribriform positive biopsies 
than in those with false negative biopsies (17% versus 11%, P=.03). Final Grade 
Group (P=.97), pT stage (P=.27) and surgical margin status (P=.24) of the radical 
prostatectomy specimens were not different between these two groups. The tumour 
volume percentage of cribriform growth at radical prostatectomy was higher in 
patients with true positive biopsies than in those with false negative biopsies, but this 
did not meet conventional measures of significance (13% versus 6%, P=.06).  
Large expansile cribriform architecture, which represents an aggressive 
subtype of invasive cribriform carcinoma, was present in 22/97 (23%) radical 
prostatectomy specimens.101 Sixteen of these 22 (73%) patients had any size 
cribriform fields on biopsy, while biopsies were false negative in 6 (27%) men. The 
false negative rate for more aggressive large cribriform architecture (6/22; 27%) was 
lower than for any cribriform architecture (39/75; 52%, P=.01). In case large 
cribriform carcinoma was present at radical prostatectomy, the tumour volume 
percentage of any cribriform growth at the operation specimens did not differ 
between men with false cribriform negative and true positive biopsies (P=.5). This 
indicates that the lower false negative rate of large cribriform growth was not merely 
due to larger total cribriform tumour percentage at radical prostatectomy.  
 
Clinicopathological outcome in Grade Group 2 patients 
Of 97 patients with biopsy Grade Group 2 prostate cancer, 73 (75%) had concordant 
Grade Group at radical prostatectomy, 20 (21%) were up-graded to Grade Group 3 
to 5, and 4 (4%) down-graded to Grade Group 1. Up-grading occurred in 9/36 (25%) 
true positive and in 9/39 (23%) false negative biopsies, and was significantly lower 
(P=.01) in true negative biopsies (2/22, 9%). Extra-prostatic expansion and surgical 
margins status were not significantly different between the three groups. 
Biochemical recurrence occurred in 21 (22%) patients and was significantly 
more frequent in the true positive (13/36, 36%) than in the false negative group (6/39, 
15%, P=.03). The true negative group (2/22, 9%) showed the lowest incidence of 
biochemical recurrence, however this difference was not significant (P=.13) when 
compared to the false negative group. 
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Table 3. Logistic regression analysis of biopsy Grade Group 2 cribriform negative prostate cancer (PCa) 
patients (n=61), predicting cribriform architecture on radical prostatectomy. 
 
Univariate 
 
Multivariable 
 
OR 95% CI P-value 
 
OR 95% CI P-value 
Age 1.1 1.0-1.2 .06  1.1 1.0-1.3 .02 
PSA (log2) 2.2
a 
1.0-4.8 .04 
 
3.3
a 
1.2-9.1 .02 
PI-RADS score        
   <5 ref       
   5 1.9 0.5-7.9 .38  1.8 0.3-9.1 .49 
Number of biopsies 0.9 0.8-1.1 .53  
0.8 0.6-1.1 .21 
Percentage PCa positive 
biopsies  
2.1 0.3-15 .47 
 
0.2 0.0-5.5 .35 
Maximal tumour length (mm) 1.1 0.9-1.2 .43  1.0 0.9-1.3 .70 
Percentage Gleason pattern 4  1.0 0.9-1.0 .70  
1.0 0.9-1.0 .36 
Presence of targeted biopsies        
   No ref       
   Yes 2.6 0.5-13 .26  1.1 0.1-10 .91 
a Per doubling unit. OR = odds ratio, CI = confidence interval. 
 
The median post-operative follow-up of Grade Group 2 patients was 27 
months (mean 18, IQR 6-40). Patients experienced biochemical recurrence after a 
median of 14 months (mean 24, IQR 5-32). Biochemical recurrence-free survival was 
not significantly different between patients with true negative and false negative 
biopsies (log rank P=.55). Patients with cribriform positive biopsies had significantly 
shorter biochemical recurrence-free survival than men with false negative biopsies 
(log rank P=.03, Fig. 1). 
 
 
Figure 1. Biochemical recurrence-free survival of biopsy Grade Group 2 prostate cancer patients, 
stratified for the presence of cribriform architecture on biopsies and subsequent radical prostatectomies 
(log rank over all groups, P-value = .03). 
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DISCUSSION 
Identification and pathologic reporting of invasive cribriform and/or intraductal 
carcinoma of the prostate are increasingly important since they are both associated 
with adverse clinical outcome.9, 82, 100, 103 Biopsy undersampling is a well-known 
problem which might have significant impact on individual patient management.105, 
108, 109 Hitherto, little is known about biopsy undersampling in identifying cribriform 
architecture. In this study we demonstrated that biopsies were false negative for 
cribriform architecture in 39% of all cases and in 40% of patients with biopsy Grade 
Group 2 prostate cancer. In false negative Grade Group 2 patients, age and PSA 
level were independent predictive parameters for presence of cribriform architecture 
on subsequent radical prostatectomy, while percentage of positive biopsies, maximal 
biopsy tumour length, percentage Gleason pattern 4 and glomeruloid growth were 
not. Patients with the more aggressive large cribriform growth pattern on radical 
prostatectomy were, however, less likely to have cribriform negative biopsies.101 
Biopsy Grade Group 2 patients with false cribriform negative biopsies showed better 
biochemical recurrence-free survival rates than men with true cribriform positive 
biopsies albeit follow-up was relatively short. 
Masoomian et al. studied concordance rates of cribriform architecture in 245 
matched biopsies and operation specimens, and found a relatively low sensitivity of 
47%, corresponding well with the 43% sensitivity in our study.110 In their subset of 
Grade Group 2 biopsy patients, false negative and true positive biopsies both had 
more advanced stage as compared to true negative biopsies on radical 
prostatectomy suggesting men with false negative and true positive biopsies have 
comparable outcome. This contrasts with our study as we found that post-operative 
biochemical recurrence-free survival of men with true positive biopsies was 
significantly shorter than of those with false negative biopsies. The difference might 
be explained by the different and relatively small cohorts of both studies. 
 While most patients with biopsy Grade Group 2 prostate cancer 
undergo active treatment, the question is rising whether surveillance could be a safe 
alternative for subgroups of this large patient population. It has for instance been 
proposed that patients with biopsy Grade Group 2 prostate cancer and low Gleason 
pattern 4 percentage should be considered for surveillance.111, 112 Others have 
suggested that biopsy Grade Group 2 prostate cancer patients without invasive 
cribriform and/or intraductal carcinoma might be eligible for surveillance.83, 102 To 
further support clinical decision tools, it is important to get insight in the false negative 
rate of potentially aggressive disease parameters and to determine how this rate can 
be minimised to an acceptable level. In the current study, we showed that 
consideration of PSA level, which is an important parameter for active surveillance, 
might prevent men with potentially aggressive false negative biopsies from being 
abstained from immediate treatment. Furthermore, presence of a PI-RADS 5 lesion 
on multiparametric MRI might also be indicative of more aggressive disease. Truong 
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et al. identified cribriform morphology in combined systematic and targeted biopsies 
in 37% of PI-RADS 5, 24% of PI-RADS 4 and 6% of PI-RADS 2 lesions, suggesting 
that high-grade MRI lesions are related to more aggressive tumours with cribriform 
morphology.113 Prendeville et al. identified cribriform morphology in 8% of PI-RADS 
3/4 lesions and in 39% of PI-RADS 5 lesions, indicating that PI-RADS score might 
be a predictor for cribriform positive prostate cancer.114 Here we showed that 56% 
of false negative biopsies had a PI-RADS 5 lesion as compared to 27% of true 
negative biopsies. However, due to the small number of patients that had undergone 
MRI, PI-RADS score was not a predictor for cribriform architecture in logistic 
regression analysis. 
We were not able to find any predictive value of biopsy percentage Gleason 
pattern 4 or glomeruloid growth pattern for cribriform architecture on radical 
prostatectomy. Presence of cribriform architecture has been associated with higher 
percentage Gleason pattern 4 on biopsies. In a cohort of 370 biopsy Grade Group 2 
prostate cancer patients, we found cribriform architecture in 6% of men with <10% 
Gleason pattern 4, in 22% of men with 10-25% pattern 4, and in 44% of men with 
25-50% pattern 4. Nevertheless, biopsy percentage Gleason pattern 4 was not 
predictive for cribriform architecture in false negative biopsies. This paradoxical 
outcome could be explained by the low level of concordance between percentage 
Gleason pattern 4 on biopsy and matched radical prostatectomy specimens in this 
study. Similarly, glomeruloid Gleason pattern 4 which has been hypothesised to 
represent a precursor lesion of cribriform growth, was not associated with cribriform 
architecture in false negative biopsies.92 
Amongst patients with cribriform architecture, those with large expansive 
cribriform fields have the worst outcome.101 The false negative rate of 27% for large 
cribriform pattern is significantly less than the rate of 52% for overall cribriform 
morphology. Since 44% of true positive biopsies had large cribriform fields on radical 
prostatectomy as compared to only 15% of false negative biopsies, this might explain 
the significantly better biochemical recurrence-free survival of false negative 
biopsies as compared to true positive biopsies, in addition to other 
clinicopathological confounding factors. 
The strong points of this study are the detailed histological review of 
matched biopsies and radical prostatectomies. The study is however limited by its 
low number of patients, the heterogeneity of the study population including both 
patients with first-time diagnosis and progression during active surveillance, and 
variability of diagnostic work-up encompassing systematic and/or targeted biopsies 
as well as multiparametric MRI assessment. Finally, follow-up is relatively short with 
a median of 27 months. 
In conclusion, we demonstrate that 40% of men with biopsy Grade Group 2 
prostate cancer were false negative for invasive cribriform and/or intraductal 
carcinoma. Age and PSA were independent predictors for cribriform architecture in 
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false negative biopsies, while patients with false negative biopsies more frequently 
had PI-RADS score 5 lesions than men with true negative biopsies. Multimodal 
evaluation of biopsy Grade Group 2 prostate cancer patients could therefore identify 
men with true cribriform negative biopsies who might become eligible for active 
surveillance. 
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ABSTRACT 
Aims: Prostate cancer heterogeneity and multifocality might result in different 
Gleason scores (GS) at individual biopsy cores. According to World Health 
Organization/ International Society of Urologic Pathology (WHO/ISUP) guidelines, 
the GS in each biopsy core should be recorded with optional reporting of overall GS 
for the entire case. We aimed to compare the clinicopathological characteristics and 
outcome of men with overall biopsy GS 3+4 = 7 with highest GS 3+4 = 7 (HI = OV) 
to those with highest GS > 3+4 = 7 (HI > OV).  
 
Methods and results: Prostate cancer biopsies from the European Randomised 
Study of Screening for Prostate Cancer (ERSPC) were revised according to 
WHO/ISUP 2014 guidelines (n = 1031). In total, 370 patients had overall GS 3+4 = 7, 
60 of whom (16%) had had at least one biopsy core with GS 4+3 = 7 or 4+4 = 8. 
Men with higher GS than 3+4 (HI > OV) in any of the cores had higher age, prostate-
specific antigen (PSA) level, number of positive biopsies, percentage tumour 
involvement, percentage Gleason grade 4 and cribriform or intraductal growth (all 
P<.05) than those with GS 3+4 = 7 at highest (HI = OV). In multivariable Cox 
regression analysis, including PSA, percentage positive biopsies and percentage 
tumour involvement, biochemical recurrence-free survival after radical 
prostatectomy (P=.52) or radiotherapy (P=.35) was not statistically different between 
both groups.  
 
Conclusions: Among patients with overall GS 3+4 = 7, those with highest 
GS > 3+4 = 7 had worse clinicopathological features, but clinical outcome was not 
statistically significant. Therefore, the use of overall GS instead of highest GS for 
clinical decision-making is justified, potentially preventing overtreatment in prostate 
cancer patients.  
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INTRODUCTION 
Gleason score (GS) at diagnostic biopsy is an important parameter for therapeutic 
decision-making in men with prostate cancer. According to the International Society 
of Urologic Pathology (ISUP) and World Health Organization (WHO) guidelines, 
pathologists should grade each biopsy containing cancer separately, provided that 
individual cores can be identified, and may also give an overall score for the entire 
case.36, 115 However, prostate cancer heterogeneity and multifocality might result in 
variability of individual biopsy core GS. In such cases it is not evident which GS 
should be recorded for patient stratification and treatment. For instance, a patient 
might have one biopsy core presenting with 6 mm GS 3+3 = 6 and another biopsy 
core with 2 mm GS 4+3 = 7. In this case, stratification might be based either on the 
overall GS 3+4 = 7 or highest GS 4+3 = 7. Discordancy between overall and highest 
GS particularly affects men with GS 7, as optimal individual therapeutic strategies 
are not well defined in this subgroup.116 Studies on overall and highest GS show 
conflicting results, and have not focused on GS 3+4 = 7 in particular.117-120 We aimed 
to compare the clinicopathological characteristics and outcome of men with overall 
biopsy GS 3+4 = 7 with highest GS 3+4 = 7 (HI = OV) to those with highest 
GS > 3+4 = 7 (HI > OV).  
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MATERIALS AND METHODS 
Patient selection 
Prostate biopsies were taken in the scope of the European Randomised Study of 
Screening for Prostate Cancer (ERSPC) section Rotterdam, initial screening round, 
the trial protocol of which has been published previously.121, 122 Each individual 
biopsy core was included in a separate container facilitating detailed pathological 
evaluation. Three investigators (C.F.K., I.P.K., G.V.L.) reviewed all prostate biopsies 
taken between November 1993 and March 2000 according to WHO/ISUP 2014 
guidelines.9, 36, 83, 115 Cases were excluded when no slides were present for review 
or when metastasis was present at time of diagnosis. For each biopsy core GS, 
percentage tumour involvement, the presence of invasive cribriform or intraductal 
carcinoma (CR/IDC) and percentage Gleason 4 was recorded. Overall GS was 
determined by adding the most common and the highest grade in all biopsy cores. 
Highest GS referred to the individual biopsy core with the maximal GS of all biopsy 
cores. Percentage tumour involvement was defined as the total tumour length 
including intervening benign glands (mm) divided by the total biopsy length (mm). 
Percentage Gleason grade 4 was defined as the relative amount of Gleason grade 
4 compared to the total number of tumour glands. 
Clinical follow-up 
Patients were monitored semi-annually after diagnosis and initial treatment to assess 
potential progression and secondary treatment. Biochemical recurrence after radical 
prostatectomy (RP) was defined as two sequential prostate-specific antigen (PSA) 
levels of ≥ 0.2 ng/ml, or any PSA increase > 2 ng/ml higher than the lowest PSA 
value after radiotherapy (RT).123, 124 An independent cause-of-death committee 
reviewed cause of death, including deaths related to screening within the prostate 
cancer deaths, and determined disease-specific survival (DSS).125 
Statistical analysis 
Categorical parameters were analysed using Pearson’s chi-square (χ2). Normally 
distributed continuous parameters were analysed using the Student’s t-test and non-
normally distributed continuous parameters with the Mann–Whitney U-test. Crude 
and adjusted hazard ratios (HRs) for biochemical recurrence-free survival (BCRFS) 
and DSS were estimated using Cox regression analysis, in which men lost to follow-
up or death of other causes were censored. P-values were calculated using the 
likelihood-ratio test, considering two-sided P-values of < .05 as statistically 
significant. All statistics were performed in R version 3.2.2 (R Foundation, Vienna, 
Austria).  
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RESULTS 
Patient characteristics 
The mean age of the entire study population (n = 1031) was 66 years (median: 67, 
interquartile range (IQR): 62–71) and the mean follow-up was 13 years (median: 15, 
IQR: 9.4–16). At the time of diagnosis, mean PSA level was 8.8 ng/ml (median: 5.6, 
IQR: 3.9–8.8), with an average of three positive biopsies (median: 2, IQR: 1–4). In 
932 of 1031 patients (90%), overall and highest GS were identical, while 98 men 
(10%) had an overall GS lower than the highest GS (Table 1). One patient presented 
with highest GS 3+5 = 8 but overall GS 4+5 = 9, explained by the presence of 
another biopsy with 4+3 = 7.  
Table 1. Overall and highest biopsy Gleason scores of the entire cohort (n=1031). 
     Overall Gleason score    
Highest Gleason score   GS 6 GS 3+4=7 GS 4+3=7 
GS 
8 
GS 9-
10 
Total 
 GS 6 
 486 0 0 0 0 486 
 GS 3+4=7 
 0 310 0 0 0 310 
 GS 4+3=7 
 0 54 50 0 0 104 
 GS 8 
 0 6 19 38 1 64 
 GS 9-10   0 0 0 19 48 67 
 Total 
 486 370 69 57 49 1031 
 
Clinicopathological characteristics of biopsy GS 3+4=7 
In total, 370 men had overall biopsy GS 3+4 = 7, 60 of whom (16.2%) had at least 
one core with a higher GS (HI > OV); 54 of 370 (14.6%) had the highest GS 4+3 = 7 
and six of 370 (1.6%) GS 4+4 = 8. Age (P = .016), PSA (P<.001), number of positive 
biopsies (P<.001), percentage tumour involvement (P=.001), presence of CR/IDC 
growth (P<.001) and percentage Gleason grade 4 (P<.001) were all significantly 
higher in men with GS 4+3 = 7 or 4+4 = 8 in individual cores (HI > OV) than in men 
with highest GS 3+4 = 7 (HI = OV; Table 2). As primary treatment, a total of 146 men 
(39%) underwent RP, 195 (53%) received RT, 25 (8%) were included in an active 
surveillance protocol and three (1%) received endocrine therapy; treatment was 
unknown in one case. 
Clinical outcome of biopsy GS 3+4=7 
The mean follow-up of the overall GS 3+4 = 7 cohort was 13 years (median: 14, IQR: 
9.6–17). Primary treatment of men with a biopsy core with GS 4+3 = 7 or GS 4+4 = 8 
was significantly more often RT (41 of 60; 68%) than of patients without higher GS 
(154 of 310; 50%; P=.012). BCR occurred in 35 of 146 (24%) men after RP and 72 
of 195 men (37%) after RT.  
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Extra-prostatic extention at RP was present in 37 of 129 cases with highest 
GS 3+4 = 7 (HI = OV) at biopsy (29%) and in nine of 17 cases (53%) with highest 
GS > 3+4 = 7 (HI > OV; P=.054), with one case presenting with seminal vesicle 
invasion. Surgical margins at RP were positive significantly more often in men with 
a biopsy core with GS 4+3 = 7 or GS 4+4 = 8 (10 of 17; 59%) than in men with 
highest GS 3+4 = 7 (38 of 129; 29%; P=.03). As we did not have information on the 
modified GS at RP according to ISUP/WHO 2005 or 2014 guidelines, we were 
unable to compare GS at RP. Although the presence of a higher GS in men with 
overall GS 3+4 = 7 (HI > OV) approached significance in predicting BCRFS after RP 
in univariate analysis (HR: 2.1, 95% confidence interval (CI): 0.91–4.8; P=.08), no 
relation was found when PSA, number of positive biopsies and tumour involvement 
were taken into account (HR: 1.4, 95% CI: 0.50–3.9; P=.52; Table 3).  
 
 
Table 2. Clinicopathologic characteristics of prostate cancer patients with overall GS 3+4=7 and highest 
GS 3+4=7 (HI=OV) or GS >3+4=7 (HI>OV).  
 Mean (median, IQR) or n (%)  
 Highest GS 3+4=7 
(n=310) 
Highest > GS 3+4=7 
(n=60) 
P-value 
Age (years) 67 (67, 62-71) 68 (69, 65-73) .016a 
PSA (log2, ng/ml) 2.7 (2.5, 2.0-3.2) 3.3 (3.2; 2.5-4.2) <.001
b 
Number of positive 
biopsies 
2.9 (3.0, 2.0-4.0) 4.4 (4.0, 3.0-6.0) <.001b 
Tumour involvement (%) 43 (43, 26-57) 53 (55, 37-66) .001b 
Presence of CR/IDC 54 (17) 34 (57) <.001c 
Gleason grade 4 (%) 16 (13, 6.5-23) 33 (36, 27-40) <.001b 
Disease specific death 14 (5) 9 (15) .005c 
aStudents t-test, bMann-Whitney U, cChi-Squared. 
 
 
Table 3. Uni- and multivariable analysis of biochemical recurrence free survival after radical 
prostatectomy.  
 Univariate  Multivariable 
  HR 95% CI P-value   HR 95% CI P-value 
Age (years) 1.0 0.95-1.1 .49  1.0 0.94-1.1 .74 
PSA (ng/ml)a 1.2 0.82-1.8 .33  1.1 0.71-1.8 .63 
Positive biopsies (%)  3.7 0.85-16 .08  2.6 0.48-14 .27 
Tumour involvement (%) 2.2 0.50-9.8 .30  2.0 0.44-9.1 .38 
Higher Gleason score  2.1 0.91-4.8 .08   1.4 0.50-3.9 .52 
aPer doubling unit. CI, confidence interval; HR, hazard ratio 
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Presence of a GS > 3+4 = 7 (HI > OV) on biopsy was associated with 
BCRFS after RT in univariate analysis (HR: 2.4, 95% CI: 1.5–4.0; P<.001). In 
multivariable analysis, percentage positive biopsies (HR: 7.8, 95% CI: 2.7–23; 
P<.001) and percentage tumour involvement (HR: 4.1, 95% CI: 1.3–13; P=.015) 
were associated significantly with BCFRS, while the presence of a higher GS was 
not (HR: 1.3, 95% CI: 0.75–2.3; P=.35; Table 4). In total, 21 men (11%) died of 
prostate cancer after RT and one after RP. Presence of a higher GS in overall GS 
3+4 = 7 patients (HI > OV) was associated with DSS after RT in univariate analysis 
(HR: 3.4, 95% CI: 1.5–8.9, P=.005), but not in multivariable analysis (HR: 1.8, 95% 
CI: 0.71-4.7; P=.21; Table 5). 
 
 
Table 4. Uni- and multivariable analysis of biochemical recurrence free survival after radiation therapy.  
 Univariate  Multivariable 
  HR 95% CI P-value   HR 95% CI P-value 
Age (years) 1.0 0.95-1.0 .90  1.0 0.96-1.1 .79 
PSA (ng/ml)a 2.0 1.7-2.5 <.001  1.7 1.4-2.1 <.001 
Positive biopsies (%) 20 7.7-52 <.001  7.8 2.7-23 <.001 
Tumour involvement (%) 7.6 2.7-21 <.001  4.1 1.3-13 .015 
Higher Gleason score 2.4 1.5-4.0 <.001   1.3 0.75-2.3 .35 
aPer doubling unit. CI, confidence interval; HR, hazard ratio  
 
 
Table 5. Uni- and multivariable analysis of disease specific survival after radiation therapy.  
 Univariate  Multivariable 
  HR 95% CI P-value   HR 95% CI P-value 
Age (years) 1.1 0.97-1.2 .186  1.1 0.98-1.2 .12 
PSA (ng/ml)a 2.2 1.5-3.3 <.001  1.8 1.2-2.8 .0045 
Positive biopsies (%) 29 5.0-167 <.001  8.4 1.2-59 .03 
Tumour involvement (%) 19 2.5-146 .004  12 1.1-122 .04 
Higher Gleason score 3.4 1.5-8.9 .005   1.8 0.71-4.7 .21 
aPer doubling unit. CI, confidence interval; HR, hazard ratio 
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DISCUSSION 
In the current study, we showed that 16% of men with overall biopsy GS 3+4 = 7 had 
at least one biopsy containing GS 4+3 = 7 or GS 4+4 = 8. These patients presented 
with higher PSA, more positive biopsies, higher percentage tumour involvement and 
more frequent CR/IDC growth. Despite these adverse features, presence of biopsies 
with higher GS (HI > OV) was not an independent predictive parameter for BCFRS 
after RP or RT when PSA, number of positive biopsies and percentage tumour 
involvement were taken into account.  
Our findings are in concordance with those of Berney et al., who showed 
that overall and worst biopsy GS have similar predictive value for prostate cancer 
death in conservatively treated patients, and Tolonen et al., who showed a similar 
result for BCRFS after endocrine therapy.117, 120 The rationale for using overall GS is 
the assumption that all biopsies are derived from one heterogeneous prostate 
cancer, and thus all single patterns should be considered part of the same tumour. 
Conversely, tumour multifocality is the motivation to consider the highest GS as the 
most relevant. As biopsies with different GS might represent separate tumours with 
variable GS, use of the highest GS precludes unwarranted down-grading of an 
aggressive tumour due to contamination with separate tumours with lower GS.126, 127 
Muezzinoglu et al. showed that the number of positive biopsies was not correlated 
with the number of tumour foci found in RPs, and we are not aware of other studies 
relating biopsy location outcomes to separate multifocal tumours at RP.128 
The findings of this study and others indicate there is no scientific evidence 
for the preferential use of either overall or highest GS in clinical practice.117, 120 Biopsy 
GS is an important parameter for clinical decision-making in prostate cancer 
patients, and although overall and highest GS are concordant in most patients, 
discordancy might lead to uncertainty on further treatment decisions. If the highest 
GS is considered, this might lead to overtreatment in a significant number of men. In 
order to prevent this, therapeutic decisions could be based on overall GS as long as 
other parameters such as PSA and number of positive biopsies are taken into 
account. 
Even though patients with overall GS 3+4 = 7 but individual cores with higher 
GS than 3+4 = 7 (HI > OV) had adverse clinicopathological features, this did not 
account independently for worse outcome. This paradoxical result could be 
explained by influence of tumour volume parameters. When the highest GS was 
higher than the overall GS (HI > OV), by definition at least two biopsy cores were 
involved, while patients with one positive biopsy core always have similar overall and 
highest GS. In addition, men with dissimilar highest and overall GS generally have a 
higher tumour involvement of all biopsies ‘compensating’ for overall GS down-
grading. In this study, both the number of positive biopsies and percentage tumour 
involvement were, indeed, independent parameters for BCRFS after RP and DSS. 
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While most men with GS 3+4 = 7 will be offered active treatment, active 
surveillance is considered increasingly in this group of patients.129, 130 Generally, 
urologists will be hesitant to consider surveillance if individual biopsy cores contain 
GS 4+3 = 7 or GS 4+4 = 8, as this implicates the presence of aggressive disease 
components. It is acknowledged increasingly that histopathological parameters 
beyond GS such as percentage Gleason grade 4, the presence of invasive cribriform 
growth or intraductal carcinoma contribute significantly to risk stratification. For 
instance, men with non-cribriform GS 3+4 = 7 have similar BCRFS and DSS to those 
with biopsy GS 6, while patients with cribriform GS 3+4 = 7 behave significantly 
worse.9, 83 To support optimal individual decision-making it is important that these 
pathological parameters are reported routinely and included in risk stratification 
models. 
A limitation to our study is the sextant biopsy protocol used in the ERSPC 
first screening round, while current protocols include a significantly higher number of 
biopsies.131 In addition, multiparametric magnetic resonance imaging (MRI) was not 
performed in the early 1990s, and RNA expression profiling for risk stratification was 
not available. Although RPs performed in the scope of the ERSPC were retrieved 
and reviewed in the 1990s, respective ‘classic’ GS could not be compared with 
current modified GS. Finally, the number of men with biopsy GS 3+4 = 7 was 
relatively low in our retrospective study, limiting the power to reveal subtle 
differences between groups.  
In conclusion, we show that 16% of men with overall GS 3+4 = 7 have 
individual biopsies with a higher GS. Although these patients have adverse features 
on biopsy and RP, we found no significant difference in BCFRS or DSS between 
overall and highest GS in multivariable models. Therefore, the use of overall GS for 
clinical decision-making is justified to potentially prevent overtreatment in a 
significant number of prostate cancer patients, as long as other clinical parameters 
on tumour load are taken into account.  
 
 
82 
 
  
83 
 
 
 
 
 
 
 
 
 
 
CHAPTER VII 
 
Comparison of tumour volume parameters on 
prostate cancer biopsies 
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ABSTRACT 
Aims: Prostate biopsy reports require an indication of prostate cancer volume. No 
consensus exists on the methodology of tumour volume reporting. We aimed to 
compare the prognostic value of different biopsy prostate cancer volume 
parameters. 
Methods & Results: Prostate biopsies of the European Randomized Study of 
Screening for Prostate Cancer were reviewed (n=1031). Tumour volume was 
quantified in six ways: average estimated tumour percentage, measured total tumour 
length, average calculated tumour percentage, greatest tumour length, greatest 
tumour percentage, and average tumour percentage of all biopsies. Their prognostic 
value was determined using either logistic regression for extra-prostatic expansion 
(EPE) and surgical margin (SM) status after radical prostatectomy (RP), or Cox 
regression for biochemical recurrence-free survival (BCRFS) and disease-specific 
survival (DSS) after RP (n=406) and radiation therapy (RT) (n=508). All tumour 
volume parameters were significantly mutually correlated (R2 > 0.500, P<.001). None 
were predictive for EPE, SM or BCRFS after RP in multivariable analysis including 
age, PSA, number of positive biopsies and Grade group. In contrast, all tumour 
volume parameters were significant predictors for BCRFS (all P<.03) and DSS (all 
P<.04) after RT, except greatest tumour length. In multivariable analysis including 
only all tumour volume parameters as covariates, calculated tumour length was the 
only predictor for EPE after RP (P=.024) and DSS after RT (P=.015). 
Conclusions: All tumour volume parameters had comparable prognostic value and 
could be used in clinical practice. If tumour volume quantification is a threshold for 
treatment decision, calculated tumour length seems preferential, slightly 
outperforming the other parameters.  
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INTRODUCTION 
Men suspicious for prostate cancer receive biopsies to determine the presence and 
aggressiveness of a potential tumour. Apart from Gleason score (GS) and number 
of positive biopsies, an indication of tumour volume should be provided in pathology 
reports.132 The College of American Pathologists and the World Health Organization 
(WHO) state that either linear cancer volume or proportion of prostate tissue involved 
by cancer should be reported as parameter for biopsy tumour volume.133, 134 Biopsy 
tumour volume has been associated with outcome after radical prostatectomy (RP) 
and radiation therapy (RT), however tumour volume representation varies amongst 
studies.15-17, 135 In addition, biopsy tumour involvement is an important threshold for 
patient eligibility for some active surveillance protocols, underlining the need for 
objective and reliable tumour volume quantification.111, 136 It is yet unknown to what 
extent tumour volume parameters are mutually related and whether they all have 
similar prognostic value. The aim of this study was to compare different tumour 
volume parameters in relation to clinical outcome in a large prostate biopsy cohort.  
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MATERIALS AND METHODS 
Patient selection 
Prostate biopsy cores were taken in the scope of the European Randomized Study 
of Screening for Prostate Cancer (ERSPC), initial screening round between 
November 1993 and March 2000, of which the trial protocol has been published 
previously.121, 122 Participating men underwent sextant prostate biopsies according 
to the study protocol, with addition of extra 7th or 8th biopsy in case of an hypoechoic 
lesions Transrectal Ultrasound (TRUS). Each individual biopsy core was embedded 
in a separate container to enable detailed pathologic evaluation. Three investigators 
reviewed all prostate biopsies according to the WHO and International Society of 
Urological Pathology (ISUP) 2014 guidelines.9, 36, 83, 115 In case no slides were 
present for review or if metastasis was present at time of diagnosis, cases were 
excluded. For each patient, GS, Grade group, total number of biopsies, number of 
prostate cancer positive biopsies and tumour volume were recorded. The study was 
approved by the local Medical Ethics Committee (MEC-2018-1614). 
Tumour volume quantification 
Tumour volume was quantified in six different ways, as depicted in Fig. 1. First, 
estimated tumour percentage per core was determined by eyeballing. The average 
estimated tumour percentage for the entire case was calculated by dividing the sum 
of the estimated percentages per core by the total number of prostate cancer positive 
biopsies per patient. Second, measured total tumour length was defined as the sum 
of the tumour lengths in all biopsies containing cancer as measured in mm using a 
micro-ruler. Third, the average calculated tumour percentage was determined by 
dividing the sum of the tumour lengths of the entire case by the total length of the 
prostate cancer positive biopsies of the entire case as measured in mm using a 
micro-ruler. Fourth, greatest tumour length was defined as the maximum tumour 
length of an individual biopsy core per patient as measured by a micro-ruler in mm. 
Fifth, greatest tumour percentage was defined as the maximum tumour percentage 
on an individual core per patient. Sixth, average tumour percentage of all biopsies 
was determined by dividing the sum of the estimated tumour percentages by the 
total number of biopsies. Assessment of each tumour volume parameter included 
intervening non-malignant tissue in case more than one tumour focus was present 
within a single biopsy.14, 137 
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B     
Individual 
core 
Estimated 
percentage 
Measured tumour 
length (mm) 
Measured total core 
length (mm) 
Calculated 
percentage 
1 60 8 13 62 
2 50 7 13 54 
3 0 0 13 0 
4 10 1 13 8 
5 50 7 13 54 
6 0 0 13 0 
C   
Average estimated tumour percentage (60+50+10+50)/4= 43 % 
Measured total tumour length 8+7+1+7= 23 mm 
Calculated tumour percentage ((8/13)+(7/13)+(1/13)+(7/13))/4= 44 % 
Greatest tumour length 8 8 mm 
Greatest tumour percentage 8/13= 62 % 
Average total estimated tumour 
percentage (60+50+10+50)/6= 28 % 
 
Figure 1. Example of tumour volume quantification methods on prostate cancer biopsies of a single 
patient. A) Each individual core is reviewed. Total biopsy length is depicted in blue, whereas the red areas 
represent tumour fields. B) For each core, the tumour percentage was estimated after which the length of 
the total biopsy as well as the tumour area was measured. C) All the tumour volume parameters were 
calculated for the patient based on the biopsy measurements. 
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Clinical follow-up 
Progression and secondary treatment were recorded by semi-annually monitoring 
each patient after diagnosis and initial treatment. Biochemical recurrence (BCR) was 
defined as two successive Prostate Specific Antigen (PSA) levels of ≥0.2 ng/ml after 
RP, or any PSA increase >2 ng/ml above the lowest PSA value after RT.123, 124 An 
independent cause-of-death committee reviewed cause of death, including deaths 
related to screening within the prostate cancer deaths, and determined disease-
specific survival (DSS).125 
Statistical analysis 
Correlations between tumour volume parameters were calculated using the 
Pearson’s R2 correlation coefficient. Parameters were log-transformed to normalise 
data for logistic regression analysis. Crude and adjusted odds ratios (OR) were 
estimated for extra-prostatic expansion (EPE, pT stage ≥3) and surgical margins 
(SM) status using logistic regression. Hazard ratios (HR) for biochemical-recurrence 
free survival (BCRFS) and DSS were estimated using Cox regression analysis, in 
which men lost to follow-up or death of other causes were censored. Multivariable 
logistic regression analysis with each separate tumour volume parameter was 
corrected for age, PSA, number of positive biopsies and Grade group. P-values of 
<.05 were considered statistically significant. All statistical analysis were performed 
in R version 3.2.2 (R, Vienna, Austria).  
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RESULTS 
 
Patient characteristics 
At time of diagnosis, the median age of the entire cohort (n=1031) was 67 years 
(interquartile range (IQR) 62-71 years) and median PSA level was 5.6 ng/ml (IQR 
3.9-8.8 ng/ml). In total 486 men were diagnosed with GS 6 (Grade group 1) on 
biopsy, 370 with GS 3+4=7 (Grade group 2), 71 with GS 4+3=7 (Grade group 3), 55 
with GS 8 (Grade group 4) and 49 with GS 9-10 (Grade group 5) prostate cancer. 
Four hundred six men (39%) were treated with RP, 508 men (49%) received RT, 8 
men (1%) underwent endocrine therapy and 108 men (11%) were put on watchful 
waiting, while treatment was unknown for one patient. The median follow-up was 13 
years (IQR 8.7-17 years). 
Correlation between tumour volume parameters 
In total 549 (53%) men received 6 biopsies, 460 (45%) 7 biopsies and 22 (2%) 8 
biopsies. The mean total positive biopsy length per patient was 26 mm (IQR 12-36 
mm) and the mean total tumour length was 11 mm (IQR 2.4-16 mm). The median 
estimated and calculated tumour percentages were 33% (IQR 15-55%) and 33% 
(IQR 15-55%) respectively. Average estimated tumour percentage strongly 
correlated with the average calculated tumour percentage (R2=0.98, P<.001). 
Measured total tumour length moderately correlated with calculated tumour 
percentage (R2=0.71, P<.001). The median greatest tumour length was 4.5 mm (IQR 
2.0-7.8 mm) and the median greatest tumour percentage was 50% (IQR 20-80%). 
Both parameters correlated moderately with calculated tumour percentage (R2=0.84 
and R2=0.87, respectively). Average tumour percentage of all biopsies (median 12%, 
IQR 3.7-26%) correlated moderately with calculated tumour percentage (R2=0.74, 
Fig. 2). Since average estimated tumour percentage and calculated tumour 
percentage were strongly correlated, and estimated tumour percentage is more 
easily established in daily practice, we excluded average calculated tumour 
percentage from further analysis.  
Pathologic features at radical prostatectomy 
Of the 406 patients treated with RP, 98 men (24%) had EPE and 101 men (25%) 
had positive SM. Since RP specimens were not available for review we did not have 
information on the contemporary GS or Grade group. All tumour volume parameters 
were strongly associated with EPE (all P<.001) and SM status (all P<.01) in 
univariate analysis (Suppl. Table 1). In multivariable analysis including all tumour 
volume parameters as covariates, calculated tumour length was the only significant 
predictive parameter for EPE (P=.024), whereas none of the parameters were 
predictive for SM status (Table 1). Multivariable analysis including age, PSA level, 
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Grade group, number of positive biopsies and each of the tumour volume parameters 
separately revealed that none of the biopsy tumour volume parameters had 
independent predictive value for EPE or SM status (Suppl. Table 1). In contrast, PSA 
and Grade group were independently associated with EPE (Suppl. Table 2). 
 
Figure 2. Schematic representation of Pearson correlations between six different tumour volume 
parameters. Correlation values can range between 0 and 1, where 1 is the highest possible correlation. 
 
Table 1. Multivariable analysis of all tumour volume parameters on outcome after radical prostatectomy, 
including all tumour volume parameters as covariates. 
 Extra-prostatic expansion  Surgical margin status 
 
Adjusted 
ORa 95% CI P-value  
Adjusted 
ORa 95% CI P-value 
Estimated tumour percentage  1.2 0.6-2.4 .55  1.0 0.5-1.9 .94 
Calculated tumour length  2.8 1.1-7.0 .024  2.0 0.8-4.6 .12 
Greatest tumour percentage 1.0 0.4-2.5 .91  0.4 0.2-1.1 .068 
Greatest tumour length  0.5 0.2-1.2 .11  0.9 0.4-2.2 .83 
Average tumour percentage of 
all biopsies  
0.9 0.4-2.1 .74 1.5 0.7-3.3 .32 
a Per doubling unit.  
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Outcome after radical prostatectomy and radiation therapy 
In total 85 of 406 men (20%) experienced BCR and 12 men (3%) died from their 
disease after RP. All biopsy tumour volume parameters were associated with 
BCRFS in univariate analysis (all P<.05, Suppl. Table 3). None of the parameters 
was significant in multivariable analysis for BCFRS including all five volume 
parameters (Table 2). In multivariable analysis including age, PSA level, Grade 
group, number of positive biopsies and each of the tumour volume parameters 
separately, tumour volume did not have predictive value for post-operative BCRFS, 
however age did (Suppl. Table 3). The low number of disease-specific deaths (n=12) 
did not allow statistical analysis for post-operative DSS.  
Of the 508 men who received RT, 223 (44%) experienced BCR and 73 
(14%) died of prostate cancer. In univariate analysis all tumour volume parameters 
were significantly associated with BCRFS (all P<.001, Suppl. Table 3). In 
multivariable analysis including all tumour volume parameters as covariates none of 
the parameters was significant (Table 2). Multivariable analysis including 
clinicopathologic parameters and each of the separate tumour volume parameters 
separately revealed that all individual biopsy tumour volume parameters had 
independent predictive value for BCFRS after RT (all P<.03, Suppl. Table 3), as well 
as PSA and Grade group (Suppl. Table 4). For DSS after RT, univariate analysis 
showed that all tumour volume parameters had significant predictive value (all 
P<.001, Suppl. Table 3). In multivariable analysis including all tumour volume 
parameters as covariates, calculated tumour length was the only positive significant 
predictive parameter (P=.015, Table 2). Multivariable analysis including 
clinicopathologic parameters and the separate tumour volume parameters showed 
that all biopsy tumour volume parameters except greatest tumour length had 
independent predictive value for DSS (all P<.05, Suppl. Table 3) as well as age, PSA 
and Grade group (all P<.05, Suppl. Table 4). 
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Table 2. Multivariable analysis of all tumour volume parameters on survival after radical prostatectomy 
(RP) or radiation therapy (RT), including all tumour volume parameters as covariates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Per doubling unit.  
  
 
Biochemical recurrence- 
free survival after RP  
Adjusted 
HRa 
 
95% CI 
 
P-value 
Estimated tumour percentage 1.2 0.7-2.2 .47 
Calculated tumour length 0.9 0.4-1.7 .68 
Greatest tumour percentage 0.5 0.3-1.3 .17 
Greatest tumour length 1.5 0.7-3.2 .32 
Average tumour percentage of 
all biopsies 
1.4 0.7-2.7 .34 
a Per doubling unit.  
 
   
 
Biochemical recurrence- 
free survival after RT 
 
Disease-specific survival 
after RT  
Adjusted 
HRa 
 
95% CI 
 
P-value 
 
Adjusted 
HRa 
 
95% CI 
 
P-value 
Estimated tumour percentage 1.1 0.8-1.6 .45 
 
1.2 0.6-2.4 .52 
Calculated tumour length 1.3 0.8-2.0 .30 
 
2.3 1.2-4.7 .015 
Greatest tumour percentage 1.0 0.6-.8 .93 
 
1.5 0.6-3.8 .42 
Greatest tumour length 0.8 0.5-1.4 .49 
 
0.4 0.2-1.0 .039 
Average tumour percentage of 
all biopsies 
1.2 0.7-1.8 .51   1.0 0.6-2.0 .90 
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DISCUSSION  
Biopsy tumour volume is associated with clinical outcome and represents an 
inclusion parameter in some active surveillance cohorts.138, 139 While a measure of 
tumour volume should be included in prostate biopsy reports, no consensus exists 
on the method of tumour volume quantification. In this study, we analysed six 
different methods for tumour volume reporting. We found overall moderate to good 
correlation between all tumour volume parameters. All had predictive value for EPE, 
SM status and BCRFS after RP, as well BCFRS and DSS after RT in univariate 
analysis. In multivariable analysis including all tumour volume parameters as 
covariates, calculated tumour length was the only predictor for EPE after RP and 
DSS after RT. Since their predictive value is comparable, all tumour volume 
parameters are acceptable for pathological reporting with calculated tumour length 
being slightly better in predicting some of the endpoints. 
The lack of standardisation in biopsy tumour volume parameters leads to 
use of a wide variety of parameters in clinicopathological studies. While tumour 
volume measurements are associated with adverse outcome after RP in many 
studies, results on their independent predictive value in multivariable analysis are 
inconsistent.18, 140-146 Here, we found that none of the volume parameters was 
independently predictive for BCRFS after RP. Discordant outcomes between studies 
can be explained by the application of tumour volume cut-off values in some studies, 
which might introduce study biases.147 Furthermore, the clinicopathologic 
parameters included in multivariable analyses are highly variably amongst studies, 
potentially omitting relevant confounding factors.  
The relation between tumour volume and outcome after RT has not yet been 
thoroughly studied. While greatest percentage tumour involvement was predictive 
for BCR in univariate analysis in several studies, it was not predictive when other 
clinicopathologic parameters were included in multivariable analysis.148-150 This is in 
contrast with our study, in which we show independent predictive value of tumour 
volume parameters for BCRFS and DSS after RT. This can be explained by inclusion 
of different clinicopathologic covariates, size of patient cohorts and use of continuous 
variables instead of cut-offs. 
In this study we show strong correlations between the biopsy tumour volume 
quantification methods and comparable predictive value for clinical outcome. In 
multivariable analyses including all tumour volume parameters, calculated total 
tumour volume outperformed the other quantitative parameters for prediction of post-
operative EPE and DSS after RT. In their study of multiple tumour measurements, 
Brimo et al. found total tumour length as best predictive quantifier for post-operative 
BCRFS.151 Calculated tumour length is a simple quantitative measurement that can 
objectively be assessed as compared to estimated tumour volume measurements 
and might be easily comparable between studies. A weakness of total calculated 
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tumour length is that its quantification can be time consuming when many positive 
biopsies are present, in which case an estimated tumour percentage or maximal 
tumour length might be more easy to assess. The impact of tumour volume 
assessment might be strongest on selection of patients for active surveillance. Some 
surveillance protocols include tumour volume parameters such as 20% or 50% 
tumour involvement as criteria for eligibility, stressing the importance of reliable 
tumour volume quantification.111, 136 Whereas estimated tumour percentage can be 
determined by eyeballing and is less time-consuming, it is not as not as objective as 
measuring tumour length and might result in volume overestimation in small biopsy 
specimens. A practical solution could be that estimated tumour percentage is given 
in all patients and that in case of potential surveillance eligibility objective calculated 
tumour length is added.  
A strong point of this study is its inclusion of patients from a well-
characterised screening cohort with long term follow-up. An inherent limitation of this 
screening cohort from the 1990s was that it included sextant biopsies, while current 
biopsy protocols generally include a larger number of systematic biopsies, often 
together with additional magnetic resonance imaging targeted biopsies.131 Finally, 
we were not able to re-evaluate the tumour grade at RP specimens according to the 
2014 WHO/ISUP guidelines since most of the surgical procedures were performed 
in other hospitals. 
In conclusion, all tumour volume parameters showed moderate to strong 
mutual correlation, had comparable prognostic value for outcome after RP and RT, 
and could be used in clinical practice. In case tumour quantification is a threshold for 
treatment decisions, such as eligibility for active surveillance, calculated tumour 
length seems preferential since it slightly outperformed the other parameters and is 
an objective quantitative measurement.  
 
Supplementary Tables may be found in the online version of this article. 
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CHAPTER VIII 
 
General discussion 
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INTRODUCTION 
Pathologists examine thin tissue sections under a microscope for disease diagnosis, 
and as a consequence grading is based on one single moment in time of a 
dynamically growing tumour. Transitions and mutual relations between tumour 
patterns cannot be appreciated on these thin sections. In the current chapter an 
overview will be provided of the two- and three-dimensional morphology of benign 
as well as cancerous prostate glands and the implications of our findings, with a 
special focus on the mutual relationships of cancerous growth patterns and their 
clinical relevance. 
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Pathology: a brief history  
Since the 1960’s, pathological grading of prostate cancer on biopsies and radical 
prostatectomy specimens is done using the Gleason score, which is based on the 
presence of architectural tumour growth patterns on thin two-dimensional 
hematoxylin and eosin (HE) stained tissue sections.6 It is considered the most 
important parameter for patient prognosis and clinical decision making. Since its 
development it has been subject to change but only recently there is increased 
interest for the prognostic value of individual growth patterns behind the different 
tumour grades, especially within Gleason grade 4.152, 153 It has previously been 
shown that cribriform Gleason grade 4 is associated with adverse patient outcome 
in contrast to the other grade 4 growth patterns, suggesting it could be the most 
relevant growth pattern for patient prognosis.84, 102, 154 Apart from their prognostic 
value, understanding of individual prostate cancer growth patterns could explain the 
substantial inter-observer variability amongst pathologists when assigning Gleason 
grade 4.43, 87, 155 When pathologists misinterpret Gleason grade 3 glands for Gleason 
grade 4 glands, this can have major implications for the treatment of the patient. 
Hence, it is needed to shed light on the three-dimensional growth and mutual 
coherence of the static growth patterns, and to provide evidence for their differences 
in biological behaviour and prognostic value. 
The road to three-dimensional imaging 
Better understanding the actual growth of prostate glands can be achieved when the 
structures are viewed in their original three-dimensional shape, for which 
miscellaneous techniques are available. For formalin-fixed, paraffin-embedded 
(FFPE) tissues the most commonly used method is serial tissue sectioning followed 
by staining and imaging of numerous slides, as this usually does not require 
additional expensive equipment and is the easiest method to implement in routine 
practice.40, 41, 54, 156 However, this technique is laborious and has several 
disadvantages, such as loss of detail, folds and cracks in the tissue, and distortion 
and uneven staining, which have major impact on the three-dimensional 
reconstructions. On top of that, serial sectioning removes the spatial connections 
between structures and introduces discontinuity in the three-dimensional 
renderings.157  
Thus, it would be preferred to use unsectioned tissue samples to visualise 
the glands in their original context. However, tissue is not transparent due to the 
scattering of light passing through the sample and structures deep within the tissue 
can therefore not be visualised. Scattering is caused by the refraction of light by each 
of the different molecules and cells within the tissue, and limits imaging of structures 
in thick samples. The molecular inhomogeneity causing the scattering can be 
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reduced by matching the refractive indexes of the tissue and the surrounding 
medium, leaving the tissue optically transparent. Many different protocols are 
available to achieve optical transparency, for instance simple immersion, 
hyperhydration and solvent based clearing.32, 158 However, none of these protocols 
were optimised yet for use with FFPE tissues and we found that simple immersion 
and hyperhydration protocols were not feasible for these specimens (data not 
published). For solvent based clearing, multiple protocols were published for fresh-
fixed tissues, but none were used in combination with embedded archival tissues 
yet.35, 49 Since archival FFPE tissues offer the opportunity to select and study specific 
regions and growth patterns of interest, we wanted to optimise one of the solvent 
based protocols for these tissues. In 2016 our group was the first to successfully 
apply an adapted solvent based clearing protocol on fresh and FFPE prostate tissue, 
enabling us to image fluorescent nuclear dyes as well as fluorescently labelled 
antibodies up to a depth of 800 µm.67 Below, I will discuss the findings from our three-
dimensional reconstructions of benign as well as cancerous prostate lesions and the 
implications of these findings.  
 
About benign prostate cancer mimickers 
Several benign prostate lesions present with a prostate cancer-like morphology on 
HE sections, especially atrophy and adenosis.70-72 In some cases it is even 
necessary to apply additional immunohistochemistry to distinguish them from true 
cancer.63, 64, 66 The four most commonly appearing atrophic lesions showed three-
dimensional acinar growth similar to pre-existent glands, supporting their benign 
nature and clearly distinguishing them from cancerous glands.68, 159 While 
investigating these four variants we discovered an atrophic variant not described 
before, characterised in three-dimensions by atrophic spaces with a Golgi-like 
morphology, running parallel to the prostate surface. On HE sections, these glands 
were represented by thin, elongated tubular structures. Due to its three-dimensional 
morphological similarity to the Golgi-system, we designated these glands Golgi-like 
atrophy. We consider it likely that these glands are the result of compression of pre-
existent glands, for instance by expanding benign hyperplastic nodules.159  
Another common prostate cancer mimicker is adenosis.160, 161 In fact, Beltran 
et al. recently published that adenosis can be held accountable for most false-
positive prostate biopsies.162 In stark contrast to the previous atrophic structures, our 
three-dimensional renderings showed that adenosis presented with a similar three-
dimensional architecture as low-grade prostate cancer and could only be 
distinguished by the presence of basal cells. Since its three-dimensional structure is 
so alike that of low-grade prostate cancer, one might think of adenosis as a prostate 
cancer precursor, however, data on its molecular background is contradictory. 
Whereas some studies show that adenosis might contain allelic imbalances 
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indicative for prostate cancer, it does not contain other prostate-cancer specific 
genetic abnormalities such as the TMRPSS:ERG fusion.76, 77, 163 Further molecular 
investigation of adenosis might elucidate its morphological resemblance to prostate 
cancer. 
 
Pre-malignant prostate lesions 
The most common prostate lesion considered as prostate cancer precursor is high-
grade prostate intra-epithelial neoplasia (HGPIN), however its relationship with 
invasive cancer is not entirely clear yet. For instance, multiple studies have described 
a potential continuum between HGPIN and invasive cancer, as they share similar 
genetic alterations such as 8p12-21 allelic loss.164-167 However, it is not clear yet in 
what way HGPIN and prostate cancer are connected and whether HGPIN is a true 
precursor of invasive prostate cancer.31, 168 Unfortunately, even though we sampled 
multiple HG-PIN glands for three-dimensional imaging, we were not able to visualise 
areas containing HGPIN transitioning to invasive cancer.159 
Whereas intraductal carcinoma of the prostate (IDC-p) has been 
acknowledged as a malignant lesion, it is not incorporated in the Gleason grading 
system and its origin is still under investigation.153 Some studies regard IDC-p as 
pre-existent ducts containing retrograde invading tumour cells from the vicinity.169, 
170 In contrast, others have shown that IDC-p can also exist without invasive 
carcinoma in the same specimen, and therefore postulate that it represents a 
precursor of prostate cancer.171, 172 Dawkins et al. used molecular analysis to show 
that IDC-p cannot be regarded as an extension or invasion of cancerous glands and 
showed that IDC-p does not share the same allelic losses as invasive cancer, 
suggesting that these lesions are separate events in prostate cancer evolution.173 
Currently, common thought is that IDC-p is formed by the invasion and spread of 
high-grade cancer into pre-existent ducts.174 On thin HE and immunohistochemistry 
slides potential transitions between IDC-p and invasive cancer can be seen (Fig. 
1A). We selected several of these regions for three-dimensional imaging, and found 
that the pre-existent glands containing IDC-p proliferations sprouted simple round 
tubules with scarce and scattered basal cells (Fig. 1B-D). The concept of tumour 
outgrowth could not be appreciated on thin tissue sections, however it would explain 
the scattered presence of basal cells in tumour glands surrounding IDC-p. As 
outgrowing tumour cells break through the basal cell layer of the pre-existent duct, 
they could pull along some of the basal cells. Unfortunately we were not able to 
determine the relationship between IDC-p and invasive cancer in detail since the 
IDC-p glands often proved larger than our microscopic field of view. In addition, the 
glandular crowding of these areas hindered us in distinguishing the individual 
transitions.  
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Figure 1. Transition between an intraductal gland and invasive prostate cancer. A) Immunohistochemical 
slide with intraductal carcinoma transitioning to invasive carcinoma, characterised by loss or scarce 
appearance of CK5 positive brown basal cells (arrows). B) Three-dimensional ImageJ and C) Amira 
rendering of the same case, where the intraductal gland with multiple basal cells (arrowhead) sprouts 
invasive tubules with scarce appearance of basal cells (arrow). D) Flipside of the Amira rendering, where 
the intraductal gland sprouted invasive prostate cancer tubules with scarce basal cells (arrows) as well 
as intraductal tubules with multiple basal cells (arrowheads). Original magnifications 20 ×; brown Keratin 
5 in immunohistochemistry (A); green, Keratin 8/18 and red, Keratin 5 immunostaining in three-
dimensional renderings. Scalebars: 100 µm. 
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Prostate cancer in a new dimension 
Previous studies on the three-dimensional architecture of prostate cancer used serial 
sectioning, staining and alignment of FFPE sections to investigate its underlying 
morphology. For instance, Boag et al. showed that Gleason pattern 3 tubules 
consisted of an interconnecting network of tubules.30 More recently, Tolkach et al. 
was the first to use serial sectioning on tissue from a prostate cancer patient with GS 
3+4=7, describing connections between Gleason grade 3 and poorly-formed grade 
4 glands.31 However, aforementioned results are based on single cases and lack 
investigation of multiple growth patterns. Since Gleason grades are represented by 
a multitude of individual growth patterns, we hypothesised that intact tissue imaging 
might reveal connections between other individual prostate cancer growth patterns 
as well. 
 In contrast to the traditional grading system, our three-dimensional 
renderings revealed that Gleason pattern 3 and poorly-formed, fused and 
glomeruloid Gleason pattern 4 glands formed a structural continuum. In addition, we 
found that this structural continuum was extended by transition from the Grade 4 
poorly-formed pattern into Gleason grade 5 single cells and cords.175 We defined this 
continuum as one with interconnecting tubules with decreasing diameter, where the 
vast majority of tumour cells makes contact with the surrounding stroma. On the 
other hand, we found a second morphological continuum consisting of cribriform 
Gleason grade 4 glands and solid Gleason grade 5 fields with or without necrosis, 
which we defined as glands with contiguous tumour cells, where the vast majority of 
tumour cells did not make contact with the stroma (Fig. 2). Importantly, we did not 
find transitions or connections between the glands of the first and the second 
continuum. 
Our model, consisting of two prostate cancer growth continuums, explains 
the substantial inter-observer variability of the current Gleason scoring system, as 
that assigns a tumour grade on static morphological features which in reality form a 
dynamic continuum. Many recent studies have shown that cribriform growth has an 
adverse prognosis and is highly associated with the development of metastasis, as 
opposed to other Gleason grade 4 patterns.84, 102, 154, 176 Additionally, the outcome of 
patients presenting with Gleason score 3+4=7 without cribriform growth on biopsy 
tends towards that of patients with Gleason score 3+3=6.83, 177 On the molecular 
level, two separate studies have shown that copy number alterations found in 
metastatic prostate cancer were enriched only in the cribriform growth pattern, 
indicating a clonal relation.96, 178 In addition, a recent study by Böttcher et al. revealed 
no significant differences in genetic abnormalities between Gleason score 3+4=7 
patients without cribriform and Gleason score 3+3=6 patients.94 These results are 
completely in line with the three-dimensional continuity of these patterns as revealed 
in our studies. The biological relationships between the individual growth patterns as 
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a continuum should be investigated further through molecular characterisation and 
in vivo models. 
 
 
Figure 2. Proposed model with two structural growth pattern continuums. Continuum I exists of a tubular 
continuum where the majority of tumour cells make contact with the surrounding stroma, including 
Gleason pattern 3, fused, poorly formed and glomeruloid Gleason pattern 4, and single cells and cords 
Gleason pattern 5. Continuum II comprises epithelial proliferations where the majority of tumour cells do 
not make contact with the surrounding stroma, including cribriform Gleason grade 4 and solid Gleason 
grade 5.  
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Consequences of the dynamic continua 
One of the major disadvantages of current pathological grading of prostate cancer is 
the substantial inter-observer variability in grading of Gleason grade 3, poorly-formed 
Gleason grade 4 and fused Gleason grade 4 glands, since these glands cannot 
always be well distinguished. On the other hand, the inter-observer agreement for 
the cribriform growth pattern is excellent.43, 87, 88, 98 The first dynamical continuum as 
proposed in this thesis could provide an explanation for the high inter-observer 
variability mentioned above, considering that the changing and developing tumour 
merely shows tubules transforming from Gleason grade 3 to Gleason grade 4 poorly-
formed or fused and vice versa. Considering that patients presenting with these non-
cribriform Grade 4 patterns on biopsy have outcomes tending towards that of 
patients with Gleason score 3+3=6, the inter-observer variability might not be as 
important as thought before, as long as the cribriform pattern can be distinguished.83, 
177 Glomeruloid growth cannot always be well discriminated from cribriform growth 
on two-dimensional slides. However, our three-dimensional reconstructions show 
that the glomerulations represent epithelial protrusions close to tubule splitting 
points, suggesting that the tubule splitting process might have failed at this point and 
caused cells to accumulate. This is in contrast to the epithelial proliferations present 
in the cribriform pattern. Moreover, we and others have found that the glomeruloid 
pattern had a lower proliferation rate than the cribriform growth pattern using KI67 
immunohistochemistry (data not published), which could be another indication that it 
is not a cribriform variant.179 
Lately, multiple prognostic studies have shown that cribriform growth is the 
most critical predictor for adverse outcome in prostate cancer patients, underpinning 
our finding that cribriform growth forms a separate architectural continuum.84, 101, 102, 
153, 180, 181 A natural consequence of these findings is that it is clinically most relevant 
to distinguish the patients with cribriform growth. This is especially true for patients 
presenting with Gleason score 3+4=7 on their prostate biopsy, since men without 
cribriform growth had comparable outcome to patients with Gleason score 3+3=6 
prostate cancer. Therefore, even though these patients are diagnosed with Gleason 
score 3+4=7, it might not be necessary for them to undergo therapeutic intervention; 
instead they could enrol in active surveillance protocols.57 In anticipation of this, our 
group has demonstrated the feasibility of a revised prostate cancer grading system, 
where the Gleason score and Grade group system is stratified by presence of 
cribriform growth. This proposed cGrade grading system outperformed the current 
grading system in predicting clinical outcome.182 However, it remains important to 
remember that prostate biopsies are prone to sampling artefacts. This can lead to 
undersampling with subsequent potentially false cribriform negative prostate 
biopsies and undertreatment of some patients, as we have shown before.183 
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Gleason 5 grade includes multiple growth patterns, namely single cells, 
cords and solid fields with or without comedonecrosis. We found that the single-cells 
and cords patterns showed continuity with poorly-formed Gleason grade 4 glands. 
Additionally, we found that the solid Grade 5 pattern formed a continuum with 
cribriform Gleason grade 4 glands. Where cribriform growth is defined as an 
expansile area of cancer cells without interfering stroma and punched out lumens, 
solid growth is all that as well on HE sections, lacking only the lumens.103, 184 As has 
been shown before, the proliferation rate is highest in the cribriform prostate cancer 
pattern, and this high proliferative activity is part of the aggressive nature of cribriform 
cancer.179, 185 Since we have shown that cribriform and solid patterns are part of the 
same continuum, it can be hypothesised that the increasing amount of cells 
compress the lumens in the cribriform glands, subsequently forming solid sheets of 
cells. To further support this assumption, their molecular background should be 
investigated in the future.  
Prostate cancer tubulogenesis 
It has not yet been unravelled what mechanisms lie behind prostate cancer growth 
pattern development and how they contribute to tumour invasiveness.  
Tumour branching by budding is the most commonly proposed model for 
glandular carcinomas and in 2011 Nagle et al. proposed a model for tumour budding 
in prostate cancer as alternative to the EMT model. 186-188 An important factor in 
carcinogenesis via tumour budding is the interaction between the tumour and the 
surrounding stromal cells.189, 190 This is supported by recent studies showing that 
reciprocal interactions between stroma and prostate epithelium do not only control 
normal glandular growth but can also promote carcinogenesis. 191, 192 In vitro and in 
vivo model systems show that co-culturing of prostate epithelial cells together with 
carcinoma-associated fibroblasts (CAF) or tumourigenic rat prostate mesenchymal 
cells stimulated progression of prostate cancer tumourigenesis.193, 194 In addition, 
Richards et al. showed that in vitro co-cultures of prostate organoids with stromal 
cells maintained the budding potential of the organoids.195 
Prostate cancer invasion via tumour branching could mirror embryonic 
tubulogenesis, directed by a complex system of polarity genes.188 Tubulogenesis 
has been extensively studied, and several mechanisms by which tube formation 
takes place during and after embryonic development are unravelled.186, 196 
Tubulogenesis via cord hollowing is initiated by cells forming a lumen in a cord of 
cells due to polarization. A pre-apical patch is formed, and subsequently the polarity 
proteins switch places, inducing lumen formation.197, 198 Unfortunately, the MDCK cell 
line is currently the only in vitro model in which the concept of tubulogenesis can be 
studied extensively.199 Considering prostate cancer as dynamical continua, rather 
than individual growth patterns, we hypothesise that the first continuum follows the 
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mechanism of cord hollowing through changes in polarity. Tumour cells invade via 
budding of cords Grade 5, which hollow to form poorly-formed glands and finally form 
Grade 3 glands, although this has not yet been investigated in in-vitro prostate 
cancer models. However, as it is currently impossible to follow prostate cancer 
growth patterns in time, novel in vitro or in vivo models should be developed to study 
the differentiation of growth patterns and their polarization. 
 
Implementation of three-dimensional pathology 
Imaging of intact FFPE tissues and subsequent three-dimensional reconstruction 
promises major advances in the field of pathology. However, there is still a long way 
to go before this technique could be implemented routinely and pathologists will be 
able to interpret these images as HE stained thin sections. Regular nuclear 
fluorescent stains such as DAPI or HOECHST excite at short wave lengths and are 
not able to emit their signal from thick tissue samples, and as a consequence they 
are not feasible for intact tissue imaging. Emission of fluorescent signal from thick 
tissue samples can be achieved using nuclear stains with higher wavelength, such 
as TO-PRO3 or sulforhodamine 101. After imaging, these fluorescent dyes can be 
pseudocoloured by algorithms to resemble standard HE stainings, to provide 
information about structures in deeper levels of the tissue.200, 201 Glaser et al. used 
DRAQ5 and eosin stains for thick tissue imaging and was able visualise structures 
up to a depth of 320µm, subsequently pseudocoloured these images to resemble 
the HE stain.202 In addition, they were able to use this staining on larger tissue 
samples to superficially visualise wide surface areas, enabling use of these stains 
for rapid assessment of tumour-margin surfaces. Combining these HE-like 
fluorescent stains with tissue clearing can provide pathologists with images suitable 
for diagnostic grading of superficial as well as deep volumetric images.  
Where traditional histology is done using tissue sectioning, a major 
advantage of three-dimensional imaging is its non-destructive nature. Current 
pathology protocols on prostate biopsy demand HE sections on multiple levels to 
ensure correct interpretation of the tumour, leading to waste of patient tissue and 
losing the opportunity to study this tissue later using specific immunohistochemical 
stainings or molecular markers. Optical clearing offers the opportunity to study the 
complete prostate biopsy without physical sectioning.  
However, even though these HE-like images can be interpreted more 
routinely by pathologists, implementation of three-dimensional imaging protocols is 
not easy. Several limitations arise, for example the need for robust and automated 
protocols with short processing times, the lack of cytological information on the final 
converted images and availability of pathologists trained for interpretation of these 
images. Routine tissue processing causes artefacts such as tissue shrinkage and 
dis-cohesive cancerous glands which might help the pathologists with their 
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diagnosis. However, tissue processing for fluorescent in-depth imaging does not 
cause these artefacts, and thus the pathologist misses this information.202 In 
addition, nucleoli and other cytological features necessary for accurate pathologic 
classification are not always as clearly visible in three-dimensional images as in 
routine HE stained tissues.  
To successfully implement three-dimensional pathology in routine 
diagnostics, the HE-like images should have a high resolution. However, high 
resolution images are usually obtained using confocal microscopy, which is time 
consuming and not suitable for high-throughput protocols as used in the diagnostic 
field. In order to maintain a high throughput protocol, the scanning time should be 
limited, which can be achieved by using low resolution imaging. However, especially 
in difficult cases, the pathologist needs to use a high magnification and thus high 
resolution to confirm the suspected diagnosis, and low magnifications as used in 
large-area imaging for fast processing times do not provide this detail. This calls for 
technological development of microscopes able to produce fast, high resolution 
images compatible with solvent cleared tissues. On top of that, standardised 
algorithms should be developed to objectively quantify structures at a low resolution. 
This could be applied via for instance deep learning, however this is still under 
development.203 Current two-dimensional digital pathology offers great potential for 
daily practise on regular thin slides, and the developments in that field might be 
applicable on three-dimensional images in the future.90, 204 
  
Future perspectives 
Three-dimensional imaging offers a wide range of options for further investigation of 
prostate cancer. In particular, areas with suspected transition between HGPIN or 
IDC-p and invasive cancer should be studied. In our study, we were limited by a 
small field of view and not capable of clear reconstruction of these areas. In addition, 
imaging of thick tissue samples using confocal microscopy proved time consuming. 
To enable high-throughput imaging, microscopes capable of three-dimensional 
imaging with a larger field of view and faster scanning times should be used, such 
as light sheet microscopes. For instance, Reder et al. previously showed the 
feasibility of this microscope for in depth imaging, using a water-based X-CLARITY 
optical clearing protocol.205 However, the combination of organic clearing solvents 
and light sheet microscopy is still under development, since organic clearing solvents 
dissolve plastics and erode metals, thus excluding the use of standard objectives for 
these microscopes. 
Application of fluorescent stainings combined with optical clearing also 
offers opportunities for other purposes. During resection of the prostate, it can be 
uncertain whether the surgical margins are free of tumour and currently this is 
determined on snap-frozen sections in some institutions. Using HE-like stainings, 
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Glaser imaged large surface areas for the fast detection of positive surgical 
margins.202 The non-destructive nature of optical clearing combined with large tissue 
volume imaging offers the opportunity to provide fast whole slide images whilst 
conserving tissue for further investigation. Recently, several studies confirmed the 
feasibility of this protocol in prostate and breast tissue using fluorescent HE-like 
stainings, however use of organic clearing solvent in these protocols is still under 
investigation.201, 205, 206 
There are multiple challenges when implementing three-dimensional 
imaging in digital pathology and thus daily practise. For instance, the ability to store 
large data files, use of computers capable of handling large data files and user-
friendly programs for three-dimensional renderings. At this moment, several 
applications can be used for digital pathology. For instance the Hamamatsu 
Nanozoomer, however this application is not designed to view Z-stacks generated 
with three-dimensional imaging. Currently, ImageJ and Amira are most frequently 
used for such renderings.51 Unfortunately these programs require specialised 
training and are not feasible in daily diagnostic practice, and new, more user-friendly 
applications should be developed. 
In our protocols, we have used the robust immunohistochemical markers 
Keratin 5 and Keratin 8/18, which mark the basal and luminal epithelial cells of the 
prostate. Visualising the expression of other proteins in prostate cancer would 
greatly enhance understanding of intra-tumoural heterogeneity, which plays an 
important part in tumour biology, progression and clinical outcome.207 Therefore, 
other tissue or tumour specific stainings should also be applied in solvent based 
clearing protocols. For instance, three-dimensional analysis of the ETS-related gene 
(ERG), proliferation marker KI67 or other biological markers could improve 
understanding of prostate cancer biology.208-211 Even though these markers are 
commonly used in routine FFPE immunohistochemistry, we have not been able to 
apply them using our protocol. Incorporation of antigen retrieval steps could enhance 
the feasibility of other protein markers, as well as directly labelled antibodies which 
can avoid multiple antibody incubation steps. 
 
Conclusion 
In this thesis, we have taken prostate cancer into a new dimension, showing 
that benign and malignant glands can easily be distinguished by their three-
dimensional morphology. We proposed two continua consisting of multiple prostate 
cancer growth patterns based on novel insight in the three-dimensional morphology 
of prostate cancer in fixed patient samples. Implementation the acquired knowledge 
on three-dimensional pathology in daily practice will facilitate better interpretation of 
tumour growth patterns, leading to optimisation of prostate cancer diagnosis and 
tumour grading.   
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SUMMARY 
Since prostate cancer is the most common cancer in Western men, it is important to 
understand the histopathological features that form the basis of clinical decision 
making for the patient and their relation to disease outcome. Pathological reports of 
prostate cancer include, amongst other things, the individual and global Gleason 
scores and the tumour volume. In this thesis a broader view on these important 
parameters in two- and three-dimensions is presented. Chapter I provides a short 
introduction to the current parameters used in pathological grading of prostate 
cancer, as well as an overview of methods used for three-dimensional imaging and 
reconstruction of tissue samples. In chapter II we aimed to develop a method to 
image formalin-fixed, paraffin embedded tissues without physical sectioning. We 
show that fluorescent immunostaining in combination with optical clearing could be 
used to image prostate glandular structures up to a depth of 800 µm. Subsequently, 
the unsectioned tissue could still be used for molecular analysis and standard 
histological characterisation. Thus, this imaging technique provided the opportunity 
to study the mutual relationships of prostate growth patterns in 3D and the possibility 
to do subsequent molecular characterisation. Chapter III elaborates on the three-
dimensional structures of benign and pre-cancerous epithelial lesions of the 
prostate, where we show that they are structurally different from prostate cancer. 
Although multiple lesions mimic prostate cancer on two-dimensional slides, only 
adenosis showed a three-dimensional tubular organisation similar to prostate 
cancer. In addition, we discovered a novel atrophic variant: Golgi-like atrophy, which 
presented with large elongated tubules parallel to the prostate surface. The three-
dimensional structure of prostate cancer is described in chapter IV. There, we 
discovered a structural continuum between Gleason pattern 3 and glomeruloid, 
fused and poorly formed Gleason pattern 4, as well as a continuum between poorly 
formed Gleason pattern 4 and cords and single cells Gleason pattern 5. On the other 
hand, we showed that cribriform Gleason pattern 4 and solid Gleason pattern 5 
formed a separate continuum. Taking into account the adverse nature of cribriform 
growth, it is important to identify patients with cribriform growth in an early stage. 
Therefore we have investigated the degree of undersampling of cribriform growth on 
prostate cancer biopsies, particularly in men with GS 3+4=7, as optimal treatment 
still under discussion for this subgroup. In chapter V we show that biopsies are false 
negative for cribriform growth in 52% of patients with cribriform growth on the radical 
prostatectomy. We did not find any predictive clinicopathological parameters for the 
presence of cribriform growth on the subsequent radical prostatectomy in these false 
negative subgroup. However, these patients had a better biochemical recurrence 
free survival rate than patients with true positive biopsies. The tumour multifocality 
and heterogeneity in a patient might result in a difference between the Gleason 
scores per individual biopsy core and the global Gleason score assigned. To 
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determine whether there are prognostic differences, we compared the outcome of 
patients with an overall Gleason score of 3 + 4 = 7 with and without presence of a 
higher individual Gleason score in chapter VI. We found that the patients with 
presence of a higher Gleason score had adverse clinicopathologic features such as 
elevated prostate specific antigen levels, more positive biopsies and more frequent 
cribriform and/or intraductal growth. However, the presence of a higher Gleason 
score on biopsy was not an independent predictor for biochemical recurrence free 
survival after radical prostatectomy or radiotherapy when standard clinical 
parameters were taken into account. Therefore, use of overall GS in clinical practice 
is justified to prevent overtreatment of these patients. In chapter VII, we investigated 
which tumour volume could best be reported in considering pathological and clinical 
outcome. Six well-defined parameters showed comparable prognostic value and 
could all be used in clinical practice. However, in case tumour quantification is a 
threshold for treatment decisions we recommend use of calculated tumour length, 
since it slightly outperformed the other parameters. Finally, in chapter VIII the main 
findings of this thesis are summarised and reviewed in the context of current 
knowledge. Here, I discuss the limitations of the different studies and potential 
clinical implications, as well as my thoughts on future research and implementation 
of our findings.  
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Appendix I – Samenvatting  
Omdat prostaatkanker de meest voorkomende vorm van kanker is in westerse 
mannen, is het belangrijk om de histopathologische karakteristieken te begrijpen 
welke de basis vormen van klinische beslisvorming voor de patiënt, en de relatie 
ervan met het verloop van de ziekte. In pathologie rapporten van prostaatkanker 
biopten staat onder andere de individuele en globale Gleason scores en het tumor 
volume. In dit proefschrift worden deze belangrijke factoren onderzocht in twee- en 
drie-dimensies. Hoofdstuk I geeft een korte introductie over de factoren die worden 
gebruikt binnen het pathologisch graderen van prostaatkanker, samen met een 
overzicht van methoden die gebruikt kunnen worden voor het maken van drie-
dimensionale beelden en reconstructies. In hoofdstuk II streefden we naar het 
ontdekken van een methode om formaline gefixeerde, in paraffine ingebedde 
weefsels in drie dimensies te visualiseren zonder dat deze fysiek gesneden moeten 
worden. We laten zien dat een combinatie van fluorescente immuno-kleuring en het 
optisch doorzichtig maken van de weefsels gebruikt kon worden voor het zichtbaar 
maken van klierweefsel in de prostaat tot een diepte van 800 µm. Daarna kon het 
ongesneden weefsel nog gebruikt worden voor moleculaire analyse en gebruikelijke 
twee-dimensionale histologische karakterisatie. Zodoende geeft deze manier van 
beeldvorming de mogelijkheid om de groeipatronen in de prostaat in drie-dimensies 
te bestuderen met daarna de mogelijkheid tot moleculaire karakterisatie. Hoofdstuk 
III verdiept zich in de drie-dimensionale structuur van goedaardige epitheliale laesies 
en voorlopers van kanker in de prostaat, waarin we laten zien dat deze structureel 
verschillen van prostaatkanker. Hoewel deze laesies kunnen lijken op 
prostaatkanker op twee-dimensionale coupes, zagen we alleen bij adenose dezelfde 
tubulaire architectuur die ook aanwezig is in prostaatkanker. Daarbij hebben we ook 
een nieuwe atrofische variant ontdekt: Golgi-achtige atrofie, welke zich presenteerde 
met grote langgerekte buizen parallel aan de buitenkant van de prostaat. De drie-
dimensionale structuur van prostaatkanker wordt beschreven in hoofdstuk IV. We 
ontdekten een structureel continuüm tussen Gleason patroon 3 en glomeruloid, 
gefuseerd en grillig Gleason patroon 4, in verbinding met een continuüm tussen 
grillig Gleason patroon 4 en strengen en losse cellen Gleason patroon 5. Aan de 
andere kan laten we zien dat cribriform Gleason patroon 4 en solide Gleason patroon 
5 een apart tweede continuüm vormden. Omdat patiënten met cribriforme groei een 
slechte prognose hebben, is het belangrijk om deze patiënten in een vroeg stadium 
te kunnen diagnosticeren. Daarom hebben we onderzocht hoe vaak cribriforme groei 
wordt gemist in prostaat biopten, met name in mannen met GS 3+4= 7, omdat de 
optimale behandeling voor deze mannen nog steeds ter discussie staat. In 
hoofdstuk V laten we zien dat cribriforme groei wordt gemist in 52% van de 
patiënten met cribriform in hun daaropvolgende radicale prostatectomie. Daarbij 
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vonden we geen klinisch pathologische karakteristieken die voorspellend waren voor 
de aanwezigheid van cribriforme groei op de radicale prostatectomie. Deze vals 
negatieve patiënten hebben echter wel een betere biochemisch-recidief vrije 
overleving dan patiënten met waar positieve biopten. Bij multifocale en heterogene 
tumoren kan het voorkomen dat er verschillen zijn tussen de Gleason score van 
individuele biopten en de globale Gleason score die wordt toegekend aan de patiënt. 
Daarom hebben we het ziekteverloop van patiënten met een globale Gleason score 
van 3+4=7 en wel of geen aanwezigheid van een hogere Gleason score op een 
individueel biopt met elkaar vergeleken in hoofdstuk VI. We hebben gevonden dat 
de patiënten met een hogere individuele Gleason score slechtere klinisch 
pathologische eigenschappen hadden, zoals een verhoogde waarde van het 
prostaat specifiek antigen in het bloed, meer positieve biopten en vaker 
aanwezigheid van cribriforme en/of intraductale groei dan patiënten zonder een 
hogere individuele Gleason score. Daarentegen was de aanwezigheid van een 
hogere Gleason score op een biopt geen onafhankelijke voorspeller voor 
biochemisch-recidief vrije overleving na een radicale prostatectomie of radiotherapie 
wanneer andere gebruikelijke klinische factoren ook meegenomen werden in de 
analyse. Daarom is het gebruik van de globale Gleason score in de kliniek 
gerechtvaardigd zodat overbehandeling van deze patiënten voorkomen wordt. In 
hoofdstuk VII onderzochten we welke tumor volume maat het beste gerapporteerd 
kan worden in relatie tot pathologische en klinisch verloop. Zes goed omschreven 
parameters lieten allen een vergelijkbare prognostische waarde zien en kunnen allen 
gebruikt worden in de kliniek. Echter, als tumor volume een grenswaarde is voor de 
beslisvorming van behandeling de patiënt raden wij aan om het gemeten tumor 
volume te gebruiken omdat deze een net iets betere voorspeller was dan de andere 
parameters. Tot slot vat ik de bevindingen van dit proefschrift samen in hoofdstuk 
VIII in de context van de huidige kennis. Hierin belicht ik de limitaties van de 
verschillende onderzoeken en mogelijke klinische toepassingen ervan, en mijn 
ideeën voor toekomstig onderzoek en de implementatie van onze bevindingen. 
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